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ABSTRACT 
Objective: 
To investigate the effect of zinc supplementation as an adjunct in children with 
enteric fever. 
 
Design:  
Double blind, randomised, placebo controlled trial. 
 
Setting: 
Teaching hospital, Chennai, India. 
 
Participants: 
Fifty eight children aged 1 to 12 years with fever and Widal or blood culture 
positive for Salmonella typhi/ paratyphi. 
 
Intervention: 
Children with enteric fever were randomised to receive 40 mg elemental zinc 
per day (n=29) or placebo (n=29) for one week.  All children received 
intravenous Ceftriaxone (75 mg/kg every 12 hours) until 5 days after 
defervescence.  
 
Main outcome measures:  
Time taken for defervescence of fever and resolution of toxemia. 
                                                                                                                    
Results: 
All 58 children in the zinc and placebo group completed the study.  
 In the intention to treat analysis, the proportions of children with fever 
defervescence by day 3 (22 (75.9%) v 15 (51.7%), P=0.043) and by day 4 (26 
(89.7%) v 17 (58.6%), P=0.043) were significantly more in the zinc 
supplemented group than in the control group.  
 
 Resolution of toxemia was noted for more cases by day 2 in the zinc 
group than in the control group (15 (75%) v 10 (43%), P=0.054). The 
proportions of children who got discharged by day 8 (22 (75.9%) v 15 (51.7%), 
P=0.054) and by day 9 (26 (89.7%) v 17 (58.6%), P=0.054) were higher in the 
zinc supplemented children. 
 
Conclusion: 
 Zinc, when used as an adjunct along with standard antibiotic therapy in 
children with enteric fever, may cause an earlier resolution of toxemia, and also 
an earlier defervescence of fever. This is a cost effective and safe intervention. 
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INTRODUCTION 
 
 Enteric fever is a systemic infection caused predominantly by 
Salmonella enteric serotype typhi and paratyphi (A, B, and C). Many outbreaks 
of enteric fever have occurred in the past, especially in developing countries, 
causing significant morbidity and mortality. The impact of enteric fever is more 
in the developing countries due to poverty, overcrowding, unsanitary 
conditions of living and unsafe water supply.  
 
 In these areas, children are a particularly vulnerable group. Infants, 
children and adolescents in South-central and Southeast Asia experience the 
greatest burden of disease. Contaminated food and water supplies are the main 
vehicles for disease transmission hence prevention mainly focuses on 
improving sanitation, ensuring a protected water supply and identification and 
treatment of chronic carriers. These strategies prove to be a major challenge in 
the low to middle income countries. 
 
 Another strategy has been the administration of vaccines, with both oral 
and parenteral vaccines available in the market. But again, these vaccines are 
not universally available, have varying protective efficacy and are not cost 
effective for the low income countries. This has been further confounded by a 
changing epidemiological trend in enteric fever. In Sub Saharan Africa many of 
the hospital based studies now indicate that non typhi serotypes of Salmonella 
especially serotype enteritidis and typhimurium greatly outnumber typhi and 
paratyphi as causes of blood stream infection.
1
Salmonella paratyphi is now 
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increasingly responsible for a growing population of enteric fever in a number 
of Asian countries.
2
 These trends raise important questions about the usefulness 
and efficacy of typhoid vaccines in enteric fever. 
 
 The discovery of antibiotics, in the meantime, caused a paradigm shift in 
the management of enteric fever. Chloramphenicol was effectively used as a 
first line drug in the treatment of enteric fever for a long time. Due to the 
widespread use of chloramphenicol, emergence of resistant strains occurred 
over the years. Subsequently, amoxicillin and trimethoprim-sulfamethoxazole 
came into use for the treatment of enteric fever. Resistance developed to all the 
three first line drugs in the 1980s leading to multi drug resistant Salmonella 
typhi (MDRST).
1
 
 
 Research on the MDR strains led to the discovery of quinolones and 
ciprofloxacin, the wonder drug, was used as a drug of choice for MDR 
Salmonella strains for some time. Unfortunately, resistance to quinolones 
emerged due to their rampant misuse.
1
 In fact, most cases of MDR typhoid, 
with reduced ciprofloxacin susceptibility, in the United States are attributed to 
travel to the Indian subcontinent.  Currently, the drug of choice for the 
treatment of enteric fever is intravenous ceftriaxone but even with this third 
generation cephalosporin, over the years, fever defervescence has taken longer 
i.e. from 3 – 4 days initially to almost 6 – 8 days currently.3 
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   Added to the morbidity due to the disease, is the economic burden due 
to prolonged hospital stay and loss of wages for the parents. In children, the 
loss of school days leads to poor academic performance.  
 
 In this rather bleak scenario, any intervention that is beneficial but at the 
same time cost effective would be an ideal solution for a country like India. 
This alternative drug or adjunct, if discovered, would not only hasten the 
recovery and shorten the hospital stay, but would also reduce school 
absenteeism and most importantly, reduce the disease burden.  
 
             Over the past few decades micronutrients are gaining prominence in 
the field of preventive and therapeutic medicine especially infections. 
Micronutrients are essential components of our diet and play a fundamental but 
major role in disease prevention
4
 and treatment. About thirty are essential and 
cannot be synthesized in our body on a daily basis or stored in substantial 
amounts, thereby making dietary sources critical.  
 
 Zinc is one such micronutrient that is available only from animal 
sources. It is now increasingly being recognised to have a wide public health 
impact i.e. both in health and disease. Zinc is required for the effective 
functioning of multiple enzymes including enzymes involved in cell division, 
transcription and translation of genetic material.
5,6
 It is an important constituent 
of bio-membranes and other proteins. Zinc deficiency manifests as disorders of 
the immune system, skin, respiratory, gastrointestinal, skeletal and reproductive 
systems. In children, it plays an important role in growth and immune 
regulation.
5,6 
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 The role of zinc, as an adjunct, has been studied in many diseases such 
as diarrhea, respiratory tract infection, malaria, Wilson’s disease, acute 
leukemia patients on chemotherapy, age related macular degeneration, etc. But 
its beneficial effects have been definitively established only in a few conditions 
like diarrhea and Wilson’s disease.5 Zinc use in acute and persistent diarrhea 
has been studied in detail in many developing countries and has been shown to 
reduce the severity and duration of diarrhea significantly.
5,7
 
  
 Some studies have also been done to determine whether differences 
occur in zinc metabolism, at the onset of critical illness, between infected 
(septic) and non-infected subjects. These studies suggest that zinc may also 
have a beneficial effect in severe bacterial infections especially in infants.  
 
 Other studies have shown that zinc can be used with antibiotic therapy 
for the treatment of sepsis in young children. One such study, done in young 
infants, showed that zinc as an adjunct promotes early recovery from sepsis and 
reduces treatment failure when used along with antibiotics.
8
 This has been 
attributed to its immunomodulatory effect and antioxidant properties.
9
 
 
 This property of zinc has not been tested in enteric fever, which has 
assumed endemic proportions in our country. If such an intervention is found to 
be useful in enteric fever, then not only will it be cost effective but it will 
actually reduce the disease burden significantly. Zinc is a very cheap, easily 
accessible and safe intervention hence it can be used in a resource limited 
setting such as ours.  
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 In this study we are using zinc as an adjunct in the treatment of enteric 
fever, along with standard antibiotic therapy, in order to ascertain whether it 
hastens the recovery from the illness.  
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AIMS AND OBJECTIVES 
Aim:      
 To determine whether oral zinc supplementation, when used as an 
adjunct with standard antibiotic therapy, produces an early defervescence in 
children with enteric fever. 
 
Primary Objectives: 
To determine whether oral zinc when used as an adjunct with intravenous 
ceftriaxone produces  
 Early defervescence in children with enteric fever  
 Early resolution of toxemia in children with enteric fever 
 
Secondary Objectives: 
 To determine whether oral zinc when used as an adjunct with 
intravenous ceftriaxone produces reduction in the duration of hospital stay after 
start of intervention. 
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REVIEW OF LITERATURE 
 Infectious diseases of poverty (IDoP) affect the poorest population of 
the world in a disproportionate fashion. They contribute in a significant way to 
the vicious cycle of poverty begetting further poverty. This is because of loss of 
productivity due to prolonged illness, disability and also social stigma in 
disorders such as HIV/AIDS. 
 
 The Global Burden of Disease Study 2010
11
 has reported an increase of 
about 111,000 deaths globally due to malaria and other neglected tropical 
diseases namely, Chaga’s disease, leishmaniasis, African trypanosomiasis, 
schistosomiasis, cysticercosis, echinococcosis, dengue, rabies, ascariasis 
among others. The burden of disease is mainly contributed to by HIV/AIDS, 
malaria and tuberculosis. The maximum cases are concentrated in Sub-Saharan 
Africa, Asia and Latin America. In fact, the data available from these regions 
may be an underestimate because of inadequate documentation.  
 
 The social determinants that contribute and thereby compound the issue 
are – unemployment, illiteracy, poor nutrition, political instability, lack of 
access to proper sanitation, and health education among others. The physical 
environment of people in these areas also facilitates and promotes vector 
transmission thus continuing the disease cycle. 
  
 A significant proportion of the infectious diseases in the low income 
group countries (LMICs) are totally avoidable or treatable with existing 
medicines and interventions. Simple but effective interventions, to prevent and 
11 
 
treat these infections, exist but their delivery to the vulnerable and affected 
populations is very difficult due to the poor health care infra structure in most 
developing countries. Hence, the need of the hour is to shift health care from an 
institution based provider to a community based one. 
 
 In India, a substantial number of cases of infection are due to enteric 
fever. This is again due to poor hygiene and lack of sanitation in most areas. 
Enteric fever causes significant morbidity as well as mortality especially 
among children. It is a systemic disease characterized by fever and 
gastrointestinal symptoms and is caused by dissemination of Salmonella typhi 
or Salmonella paratyphi in the bloodstream.  
 
Global burden of enteric fever 
 Enteric fever occurs primarily in developing nations where sanitary 
conditions are poor. It is endemic in Asia, Africa, Latin America, the 
Caribbean, and Oceania. Eighty percent of cases come from India, Bangladesh, 
China, Indonesia, Nepal, Pakistan, and Laos. Enteric fever occurs mostly in 
underdeveloped areas, infects about 21.6 million people and kills an estimated 
200,000 people every year.
12 
12 
 
 
Global incidence of typhoid fever.
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Enteric fever in India: 
 Enteric fever remains an important public health problem in India. In 
1999, it was a significant cause of morbidity in children between 1 – 5 years of 
age, in India. In 2003, over 17 million episodes of enteric fever occurred in a 
year worldwide and resulted in 600,000 deaths. Of this more than 90% of the 
morbidity and mortality occurred in Asia. A study conducted by Leon et al
2
 
showed a significantly high incidence of enteric fever in 2 to 15 year old 
children in India and Pakistan. It has now become endemic in most parts of our 
country. 
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Multidrug-resistant strains: 
 The main barriers for control of the disease are vaccines that are not 
immunogenic in very young children and the emergence of multidrug 
resistance, which threatens the efficacy of antimicrobial therapy. Of late, 
Salmonella typhi is being replaced by infections with multidrug-resistant 
Salmonella paratyphi A. The frequent use of chloramphenicol led to emergence 
of resistant strains from 1970 onwards. In 1972, the first epidemic of 
chloramphenicol resistant strains occurred in Mexico. Since then the use of 
ampicillin and trimethoprim-sulfamethoxazole increased and trimethoprim-
sulfamethoxazole was the drug of choice till 1975. In 1975, the emergence of 
trimethoprim-sulfamethoxazole resistant strain was reported in France. More 
than 50% of strains are multi drug resistant in South-East Asia. In 2014, around 
27 million individuals were infected with Salmonella typhi worldwide. 
 
 Multidrug-resistant strains of Salmonella Typhi emerged in 1989 in 
Southeast Asia and this strain has disseminated widely since then. They contain 
plasmids encoding resistance to chloramphenicol, ampicillin and trimethoprim. 
With the increased use of fluoroquinolones to treat MDR enteric fever in the 
1990s, strains with reduced susceptibility to ciprofloxacin have emerged in 
India, southern Asia and Sub-Saharan Africa. The fluoroquinolone resistant 
strains are called as nalidixic acid-resistant strain (NARST). In 2000, an ESBL 
producing strain was detected, for the first time, in Canada. Salmonella serovar 
typhimurium strains, which were resistant to 12-15 antibiotics, were identified 
in Malaysia and Vietnam for the first time.
1 
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Areas with reported cases of MDR salmonella.
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Prevention of enteric fever: 
 The major risk factor for outbreaks of enteric fever is contamination of 
water supplies with sewage.  
 Purification of water: During outbreaks, central chlorination and 
domestic water purification is necessary.  
 Potable water supply: Safe drinking water should be available for all 
individuals. Drinking water should be boiled.  
 Food safety should be ensured: The food handlers should maintain 
personal hygiene. They should wash their hands before preparing food. 
Raw vegetables and fruits should be washed cleanly. Food should be 
cooked well before serving. Food should be served in a hygienic 
manner.  
15 
 
 Waste disposal: Proper waste disposal should be done. Use of sanitary 
latrines should be encouraged. Human waste should be disposed 
properly.  
 Health education: Health education is an effective way of prevention of 
any disease. Awareness of the disease transmission and complications 
should be taught to the public. Public awareness can be created by using 
mass media and other modalities. 
 Immunisation: Worldwide two vaccines are used at present. An oral 
live attenuated preparation, Ty21a strain of Salmonella typhi, has a good 
efficacy for 5 years. The Vi polysaccharide vaccine is used in children 
aged 2 years or more as a single intramuscular injection with a booster 
every 2 years.  
 
General intervention strategies for infections 
 The World Health Organisation (WHO) promotes the use of five public 
health strategies to control, eliminate and eradicate infections. These include 
preventive chemotherapy, innovative and intensified disease management, 
vector control and pesticide management, provision of safe drinking water, 
basic sanitation and hygiene and most importantly education. 
 
 In terms of enteric fever the most important aspects are disease 
prevention by providing good sanitation, promoting hygiene especially hand 
hygiene, provision of safe and potable drinking water and health education. If 
disease occurs then effective chemotherapy holds the key to halting the 
transmission of disease and reducing morbidity and mortality. 
16 
 
The changing care paradigm 
 Apart from a poor health infrastructure, another major issue is the lack 
of progress in the various health parameters. Major impediments to this are 
gender discrimination, low levels of female literacy, and lack of woman 
empowerment. All these, collectively, prevent women from seeking care for 
themselves and their children. This makes children a very vulnerable group. 
 
Community Based Interventions (CBIs) 
 These interventions have the potential to overcome the barriers of 
availability and access the only drawback being trained personnel to deliver 
health care at the door step. Many of the interventions targeting infectious 
diseases have been delivered to the community by community health workers 
(CHWs). 
 
 While CHWs may not be able replace sophisticated health care they can 
certainly provide health care to the unreachable since they are part of the local 
populace. 
 
Examples of low cost interventions for infections at the community level 
 Promotion of early and exclusive breast feeding until six months of age 
 Oral rehydration solution for the treatment of diarrhoeal disorders 
 Immunisation against communicable diseases at the community level 
 Use of micronutrients to prevent and treat infections  
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 Zinc is a micronutrient that is fast gaining importance in the prevention 
and treatment of many infections. Notable among them is its use in diarrhoea. 
It has been proven conclusively that administration of oral zinc in the treatment 
of acute and persistent diarrhoea reduces both the duration and severity. 
 
zinc: 
 Zinc is the 30
th
 element on the periodic table. Todd et al described the 
importance of zinc for the first time in 1934. After iron, zinc is the most 
common mineral present in our body.
13 
Structure of zinc 
 
 Zinc is present in many foods, especially such as such as liver, red meat, 
beef, pork, poultry, fish, oysters, crabs, eggs, cow’s milk, chicken and duck. It 
is also present in seeds, nuts, wheat, beans and cheese.  
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Absorption: 
 The fraction of zinc absorbed from the gut is difficult to estimate 
because zinc is also secreted into the intestines. Zinc, given as aqueous solution 
to fasting subjects, is absorbed efficiently (60-70%), whereas absorption from a 
solid diet is less efficient and varies with the zinc content and composition of 
the diet. Zinc is disintegrated as free ions during digestion. These ions may 
then bind to endogenously secreted ligands before they are transported into the 
enterocytes in the duodenum and jejunum. Specific transport proteins may help 
the passage of zinc across the cell membrane into the portal circulation. With 
high intakes, it is also absorbed through a passive paracellular route. The portal 
system takes absorbed zinc directly to the liver, and then is released into the 
systemic circulation for delivery to other tissues. Most of the zinc in the 
circulation is bound to albumin, and conditions that alter serum albumin 
concentrations can have a secondary effect on serum zinc levels.  
 
 Serum zinc represents only 0.1% of the whole body zinc. 90% of body 
zinc is localised in bone and skeletal muscle. The circulating zinc turns over 
rapidly to meet tissue needs. Many foods like cereals, legumes, and tubers, 
contain zinc, but the presence of phytate, fiber, and lignin reduces its 
absorption. Cow’s milk and soymilk further reduce the absorption of zinc.  
 
 Zinc in breast milk is well absorbed and fruits taken with cereals may 
increase the bioavailability. Zinc is absorbed throughout the small intestine by 
facilitated diffusion using transporters. Ten zinc transporters and 15 zip 
19 
 
transporters are available in human cells. They have opposite roles in cellular 
zinc homeostasis. Zinc transporters reduce intracellular zinc by promoting zinc 
efflux from cells or into intracellular vesicles, but zip transporters increase 
intracellular zinc availability by promoting extracellular zinc uptake and 
perhaps, vesicular zinc release into the cytoplasm. Zinc transporter-1 is a zinc 
exporter and plays a role in zinc homeostasis as a mechanism for zinc 
acquisition and elimination under conditions of excess.  
  
 Approximately half of all zinc eliminated from the body is through the 
gastrointestinal tract. Considerable amount of zinc is secreted in the biliary and 
intestinal secretions, but most of it is reabsorbed. 
 
Functions of zinc: 
Zinc is a component of more than three hundred enzymes in the body. It is 
present in small amounts in all tissues.  
 Zinc regulates gene transcription and participates in nucleic acid 
metabolism, and protein synthesis.
15
 
 Many enzymes are zinc dependent like DNA polymerase, RNA 
polymerase, thymidine kinase, many proteases (wound repair and 
intestinal epithelial regeneration).
14
 
 Zinc is a cofactor for thymulin which is essential for T cell 
maturation.
14,15
 
 Zinc is required for synthesis of insulin by pancreas.15 
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 Adequate zinc intake is necessary for maintaining the integrity of the 
immune system. It affects multiple aspects of the immune system, from 
the barrier of the skin to gene regulation of lymphocytes.
14
 
 Zinc plays an important role as an antioxidant agent.9,16 
 
Zinc deficiency: 
 Zinc deficiency is common in developing countries due to lack of intake 
of animal food. It is usually a part of malnutrition or malabsorption syndromes. 
Males are more commonly deficient than females, but respond more readily to 
supplementation and a large bolus dose may not be as effective as a small daily 
dose.  
 
Zinc deficiency in children 
 Young children are at increased risk of zinc deficiency because of 
increased zinc requirements during growth. Poor physical growth is an 
important feature of zinc deficiency in preschool and school-aged children. 
Delayed sexual maturation and hypogonadism is a prominent feature of zinc 
deficiency in adolescents. Anemia, anorexia, diarrhea, hair loss, dermatitis, 
impaired immune function, poor wound healing and skeletal abnormalities are 
the manifestations of zinc deficiency. Zinc deficiency also causes acro-
dermatitis enteropathica.
16 
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Impact of maternal zinc deficiency 
 Severe maternal zinc deficiency is associated with spontaneous abortion, 
and anencephaly. Milder forms are associated with low birth weight babies, 
intrauterine growth retardation and preterm deliveries.  
 
Impact of zinc deficiency on immunity 
 Zinc deficiency has adverse effects on the development and function of 
many immunological cells including T cells, B cells, and macrophages. 
Production of immunoglobulins (IgA, IgM, and IgG) is decreased. Macrophage 
activation and phagocytosis is also affected. Zinc deficiency interferes with the 
cell-mediated immune response, as thymulin is zinc dependent.  
 
 Interleukin 2 (IL2) production is greatly reduced in T- helper cells from 
zinc-deficient individuals while IL4, IL5, IL6, and IL10 are unaffected. An 
imbalance between T-helper 1 cells (TH1) and TH2 cells is noted in zinc 
deficiency. A decrease in the ratio of CD4/CD8 lymphocytes also occurs.  
 
 The concentration of zinc in plasma or serum is currently the best 
available measure of the risk of zinc deficiency. Serum zinc concentration 
estimation may have drawbacks in validity and reliability for identification of 
mild or moderate zinc deficiency.
17
 Serum zinc concentrations fluctuate, mostly 
due to the effects of food ingestion. The highest level is seen during the 
morning.  
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 Serum zinc concentrations are mostly reduced during acute infections 
and inflammation. Cytokines released during the acute phase response will 
activate hepatic metallothionine synthesis. This will alter the hepatic uptake of 
zinc. Hypoalbuminemia results in lower serum zinc concentrations. Hemolysis 
can result in extremely high serum zinc levels because the concentration of 
intracellular zinc is considerably more.
14,18 
 
Prevention of zinc deficiency: 
 
 Strategies that prevent zinc deficiency include dietary modification, 
supplementation, fortification, and bio-fortification. The normal requirement 
for children ranges between 3.5 and 5 mg per day. Acquired zinc deficiency 
can be treated with 0.5 to 1 mg of elemental zinc/ kg / day for several weeks or 
months.
14,19 
 
Use of zinc in infectious diseases: 
            Zinc deficiency results in higher rates of infectious diseases in children. 
The incidence of diarrhoea, pneumonia and serious bacterial infections is less 
in zinc supplemented in comparison to those children not given zinc. 
 
Zinc use in acute diarrhoea 
 There is a large body of literature to support the use of zinc as an adjunct 
in the treatment of diarrhoea. This supplementation can reduce both the 
severity and duration of an acute episode of diarrhoea. It is the cumulative data 
from these studies that led WHO to make zinc supplementation mandatory in 
acute diarrhoea. 
23 
 
Studies from India 
 Sachdev et al
20
, who conducted one of the earliest randomised 
controlled trials  on zinc supplementation in diarrhoea, were able to 
demonstrate a decrease in the duration and frequency of diarrhoea.
18
 They gave 
higher doses of zinc (40 mg/day) to children aged 6 – 18 months with acute, 
dehydrating diarrhoea. This intervention lead to an insignificant 9% reduction 
in the duration and an 18% reduction in the stool frequency. 
 
 They had assessed rectal mucosal zinc too and found that children with 
low rectal zinc concentrations had more dramatic reductions (33%) in both 
duration and severity of diarrhoea.
20
 
 
 Sazawal et al
21
 in 1995, studied children between 6 – 35 months age 
group. The intervention group received zinc along with vitamins A, B, D, E 
and ORS. The placebo group received only the vitamins and ORS. The 
supplemented group had a 23% risk reduction for continued diarrhoea, 39% 
reduction in the number of stools per day and a 21% reduction in the duration 
of diarrhoea. This effect was greater in children with stunting thereby 
underlining the role of zinc in growth as well as infections. 
 
 In 2000, Dutta et al
22
 studied malnourished children between 3 – 24 
months with acute diarrhoea and dehydration. In this study, significant benefits 
were noted in terms of reduction in duration, improvement in consistency of 
stool, and a reduced need for ORS. This may again be attributable to the 
malnourished status of the children recruited. 
24 
 
 Bahl et al,
23
 compared the efficacy of zinc in diarrhoea among 3 groups 
– those receiving zinc fortified ORS, zinc administered separately along with 
ORS and ORS alone in acute diarrhoea. They studied children with acute 
diarrhoea of less than three days duration, and noted that those in the 
supplemented group had a lower duration of diarrhoea and fewer total stools. In 
those receiving zinc and ORS separately, fewer total stools and improvement in 
consistency were noted. There was no effect on the duration of diarrhoea. The 
study revealed a positive correlation between low plasma zinc level and 
susceptibility to infections. They concluded that zinc given separately with 
ORS solution was found to be most efficacious in reducing the duration of 
diarrhoea 
 
 In another study by Bhatnagar et al,
24
 in 2004, zinc treatment was seen 
to reduce total stool output and stool output per day. The risk for continuation 
of diarrhoea was less and the proportion of diarrhoeal episodes was also 
reduced. This study was done only in male children between 3 – 36 months of 
age and in addition to zinc the treated group received vitamin supplementation 
also. 
 
 Patel et al
25
 looked at the predictors for cure in children under five with 
acute diarrhoea. They found that cure was less likely if the duration of 
diarrhoea prior to enrolment was greater, if intravenous fluids were used and if 
the time taken to rehydration was greater. The mean survival time and the 
median time to cure were not significantly different in the two groups. 
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 In a multi centre study done by Fischer and Walker,
26
 both pioneers in 
the research on therapeutic zinc in infections, they found the geometric mean 
duration of the diarrhoeal episode was, in fact, 0.21 days longer in the zinc 
supplemented group. This difference was not statistically significant. The study 
was done in India and Ethiopia in 2006. 
 
Studies from other developing countries 
 A huge body of research on zinc supplementation in diarrhoea and 
shigellosis has been done at the Centre for Health and Population Research at 
Dhaka in Bangladesh. They have conducted very well designed studies in 
collaboration with the Department of International Health, Johns Hopkins 
Bloomberg School of Public Health, Baltimore, USA. 
  
 In one such study Roy et al
27
 studied zinc supplementation in 
moderately malnourished children under five years of age with stool culture 
positive shigellosis. This was a randomized, double-blinded, controlled trial. 
The study was done in the age group of 1-5 years. Fifty six culture proven 
shigellosis cases were included in the study. They divided them into two 
groups, one group received zinc and another group received placebo for 2 
weeks. Both groups received standard antibiotic for 5 days. After discharge all 
the cases were followed every 2 weeks for 6 months. Children receiving zinc 
recovered significantly earlier than the control group. The disappearance of 
blood and mucous were 50% shorter in the zinc group. The mean weight gain 
of the children with zinc supplementation was significantly more than in the 
control group. The zinc supplemented group also showed fewer diarrheal 
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episodes on follow up. These two studies showed that zinc is useful in 
Shigellosis which is a gram negative sepsis and mainly involve gastrointestinal 
system.     
 
 Roy et al
28
 did a similar study in children with stool culture positive 
cholera and found that more children in the zinc group recovered by day 2 and 
by day 3 than in the control group. Zinc supplemented children had a 12% 
shorter duration of diarrhoea and a 11% less stool output than the control 
patients. These results have an important public health implication especially in 
low income countries like Bangladesh where cholera related mortality is very 
high. 
 
 Rahman et al
29
 conducted a study to assess the effect of zinc as an 
adjunct on systemic immune responses in shigellosis. They conducted a 
double-blind, placebo-controlled trial. Children aged 1 to 5 years with 
symptoms suggestive of dysentery with stool positive for Shigella flexneri were 
included in the study. All children were treated with standard antibiotic. Zinc 
and on group was given elemental zinc 20 mg per day as a syrup with 
multivitamin and calcium. Another group was given only multivitamin and 
calcium. Antibiotic was given for 5 days. Zinc and placebo were given for 14 
days. At the end of 14 days health care visitor visited all the children at home. 
Serum zinc was measured at admission, 7
th
 and 30
th
 day after enrollment. 
Rectal biopsy was done on 1
st
 and 7
th
 day after enrollment. CD20+ level was 
also done. Zinc group showed a significant effect on serum zinc concentrations 
after supplementation. Zinc group showed greater shigellacidal antibody 
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response than the control group. Proportions of circulating CD20
+
 and CD20
+
 
CD38
+
 cells, were higher on day 7 in the zinc group than in the control group. 
No effect on histopathological changes was noted between the two groups.  
 
 Strand et al
31
 studied a large cohort of children (n=449) with acute 
watery diarrhoea in Nepal. The children were aged between 6 – 35 months of 
age. They observed that the relative hazards for termination of diarrhoea were 
26%, 21% and 19% higher in the zinc, zinc with vitamin A, zinc-caretaker 
groups than in the placebo group. The relative risks of prolonged diarrhoea 
were 0.57, 0.53 and 0.55, in these groups, respectively. 
 
 Most of these studies have been done in developing countries where zinc 
deficiency is commonly seen. More importantly, most of them have been 
conducted in children with acute watery diarrhoea of unspecified aetiology 
except for the studies by Roy et al. 
  
 Haider et al
7
 reviewed the evidence and included 14 studies in the 
meta-analysis. The results showed that zinc supplementation reduced the mean 
duration of acute diarrhoea significantly as compared to the placebo group. 
 
 There was significant heterogeneity among the trials hence they did a 
sub group analysis by age group. The cut off used was 6 months or greater. 
Currently there is lack of evidence for the efficacy of zinc in infants less than 6 
months of age. 
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 As part of this review, using pooled data, Haider et al also concluded 
that zinc supplementation was associated with a marginally significant 
reduction in acute diarrhoea episodes that lasted for 7 days or more. 
 
Assessment of usage and effectiveness of zinc in diarrhoeal episodes: 
 Recently, large scale effectiveness studies using zinc in diarrhoea have 
been completed in India, Pakistan and Mali in public-private collaboration. The 
evidence shows that there is definitely an increased usage of zinc, during 
diarrhoea, by care givers resulting in much improved outcomes (Bhutta ZA et 
al 2007). 
 Bhandari et al
32
 observed that zinc supplements were utilised in 36.5% 
and 59.8% of diarrhoeal episodes in the four weeks preceding interviews in the 
intervention areas. The rates of diarrhoea and pneumonia prevalence during the 
preceding 14 days were lower in the intervention communities. This study was 
done in rural Haryana in India. 
 
 They also found that the hospitalisations due to diarrhoea and 
pneumonia were less in the preceding 3 months in the intervention group. 
 
 A similar large study was conducted in Matiari district in Pakistan. It 
was seen that when zinc supplements were distributed by the lady health 
workers to children with acute diarrhoea, there was a reduction in the 
subsequent incidence of diarrhoea and diarrhoeal mortality. This may be due to 
the repeated therapeutic courses of zinc for diarrhoea but nevertheless the 
intervention has beneficial effects overall. 
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Conclusion-Efficacy of zinc in acute diarrhoea: 
 Current evidence clearly indicates that zinc supplementation in acute 
diarrhoea in children, reduces the duration of diarrhoea by at least half a day 
(P=0.002). Hence, these results support the WHO recommendation that zinc 
supplementation should be an integral part of the management protocol in 
diarrhoea. 
 
Mechanism of action of zinc in diarrhoea: 
 
 Cyclic AMP-induced, chloride dependent fluid secretion is inhibited by 
zinc (inhibiting basolateral potassium channels), in in-vitrostudies with rat 
ileum. zinc improves the absorption of water and electrolytes, improves 
regeneration of the intestinal epithelium and increases the levels of brush 
border enzymes.
33
 These may be the mechanisms by which zinc exerts its 
action in diarrhoea 
 
Zinc supplementation as an adjunct in the treatment of children with 
persistent diarrhoea 
 Persistent diarrhoea is any diarrhoea lasting for more than fourteen days. 
It is a cause for increased morbidity and mortality. Hence interventions that can 
reduce the complication rate and death are necessary. 
 
 Sachdev et al
34
 noted a non significant reduction in the duration of 
diarrhoea in his cohort of children aged between 6 – 18 months. 
  
 Roy et al
30
 too noted a nonsignificant reduction in the duration but there 
was significant reduction in the duration in underweight children. Children in 
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the zinc group did not lose weight during hospitalisation. This study was done 
in children aged 3 – 24 months with persistent diarrhoea. 
           
 In a study from Pakistan, Bhutta et al
35
 did not observe any significant 
difference in the duration of diarrhoeal episodes between the two groups. There 
was however a trend towards shorter episodes in the children with lower serum 
zinc levels. 
  
 In Peru, Penny et al
36
 studied about 276 children with persistent 
diarrhoea and found that the duration of illness was significantly reduced in the 
zinc supplemented group. 
  
 A meta-analysis of four trials (Zinc Investigators Group; Roy 1998, 
Bhutta 1999, Penny 1999 and another trial from Bangladesh) showed a 42% 
reduction in treatment failure or death. This effect was more marked in children 
less than 1 year of age, males, children with wasting and those with lower 
baseline serum zinc levels 
  
 In a study done by Khatun et al
37
 in Bangladesh, the rate of recovery 
within 7 days was significantly greater in the zinc group. 
 
Conclusion-Efficacy of zinc in persistent diarrhoea: 
 There have been five major studies that looked at the efficacy of zinc 
supplementation in children with persistent diarrhoea. The pooled analysis of 
all this data has endorsed the benefits of zinc supplementation in reducing the 
duration of disease (reduction 0.68 days, P<0.001). 
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Zinc supplementation in serious bacterial infections 
 In a study by Bhatnagar S et al, zinc was used as adjunctive treatment 
in infants aged between 7 and 120 days with probable serious bacterial 
infection. This study was a double blind, randomized control trial. This study 
has shown that significantly fewer treatment failures occurred in the zinc 
group (34 [10%]) than in the placebo group (55 [17%]). This study showed that 
zinc could be given as adjunct treatment to reduce the risk of treatment failure 
in infants aged 7-120 days with probable serious bacterial infection.
8 
 
Zinc supplementation in children with pneumonia 
 Currently, there is insufficient evidence available on the efficacy of zinc 
supplementation in pneumonia. The mechanism by which zinc may act in 
respiratory infections is also not clearly elucidated. One of the postulated 
mechanisms is immunomodulation i.e. production of interferon and the 
inhibition of the pro inflammatory cytokines.
38 
 
 Most randomised controlled trials involving the use of zinc in 
pneumonia have been done in children under five years of age with either 
pneumonia or severe lower respiratory tract infection and most of them have 
been done in South Asia. Commonly assessed outcomes were time to recovery, 
time taken for tachypnoea and retractions to resolve, duration of hospital stay, 
hypoxia and improvement in feeding. 
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 In a study, done in India in 2002, by Mahalanabis et al,
39
 hospitalised 
children with pneumonia complicating measles were administered 20 mg of 
zinc acetate twice daily. These children received one dose of one lakh units of 
vitamin A in addition. 
 
 On analysis, using the Cox proportional hazards model, it was seen that 
there was no significant difference in the time taken for resolution of fever, 
tachypnoea, return of appetite and cure between the two groups. This study was 
done in children between 9 months to 15 years of age. 
 
 Bose et al,
40
 in their 2006 study from India, studied the effect of zinc 
supplementation in children, less than two years of age, hospitalised with 
severe pneumonia. Twenty milligrams of zinc sulphate was administered on 
day 1 and followed up with 10 mg from day 2 onwards. They too did not find 
any clinically or statistically significant differences in the duration of 
tachypnoea, hypoxia, retractions, feeding difficulty and lethargy between the 
two groups. 
 
 Two randomized controlled trials from Bangladesh and India, studied 
the effect of zinc supplementation along with antibiotics, in reducing the 
severity of pneumonia in children less than 2 years of age.A 30% reduction in 
the duration of severe pneumonia was noted. One other trial from Kolkata 
reported significantly increased recovery rate by 2.6 times in comparison to 
controls.  
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 Brooks et al
41
 studied the role of zinc as an adjuvant in the treatment of 
pneumonia i.e. whether it reduces the duration of illness. The study, done in 
Bangladesh, showed clinically and statistically significant reductions in 
recovery time from severe pneumonia in children less than 2 years given zinc 
with standard antimicrobial therapy. They noted that the duration of severe 
pneumonia, retractions, tachypnoea, hypoxia and duration of hospitalisation too 
was less in the zinc supplemented group as compared to the placebo group. 
  
 Mahalanabis et al
42
 conducted another study in India, in 2004. This 
was in hospitalised children with severe acute lower respiratory infection. 
These children, less than two years of age, received both oral zinc (10 mg) and 
vitamin A. They were randomised into four groups. Upon analysis, a 
statistically significant recovery from a very ill status and resolution of fever 
was noted in the zinc treated group while there was no significant difference in 
terms of tachypnoea and feeding difficulty. An unusual finding in this study 
was that these results were observed in boys alone, an observation that could 
not be explained. 
 
 In the only RCT available from Australia, Chang et al
43
 studied 
children less than 11 years of age hospitalised with acute lower respiratory 
infections (ALRI). In this study too there were four randomised groups with 
permutations and combinations with vitamin A. Oral zinc was administered for 
5 days. This study was unusual in that a much higher dose of zinc was 
administered (20 mg in children less than 1 year of age and 40 mg in children 
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more than 1 year of age) They did not observe any clinical benefit due to zinc 
supplementation in terms of time taken to resolution of fever or tachypnoea, or 
hospital stay. In fact, children supplemented with zinc had an increased risk of 
readmission for ALRI within 120 days. 
 
 In all these studies, treatment doses of zinc were at least twice the RDA 
and supplementation was given for 5 to 6 days or until recovery. All children in 
the studies were given standard antibiotic therapy. Only in two of these 5 trials 
did the children a significantly faster recovery from pneumonia than those 
receiving placebo. 
 
 Baseline serum zinc levels were measured in all the studies but 
differences in these levels did not impact the treatment effect. 
 
Conclusion - Efficacy of zinc in pneumonia 
 Analysis of all these studies showed nonsignificant effects of zinc on the 
outcomes assessed in children with pneumonia. 
 
Zinc supplementation in children with malaria 
 Only one multicentre study has been identified with respect to zinc 
supplementation which was conducted by the Zinc Against Plasmodium Study 
Group.
44
 This study was conducted at five sites namely Ecuador, Ghana, 
Tanzania, Uganda, and Zambia. Inclusion criteria were children aged 6 months 
to 5 years with fever and more than 2000 or more asexual forms of Plasmodium 
falciparum per microliter in a thick blood smear. 
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 All children were treated with chloroquine and randomly assigned to the 
intervention or placebo group. The median time taken for fever defervescence 
was not significantly different in both the groups. There was no difference in 
the clearance rates of parasitemia or change in the haemoglobin concentration 
between the two groups. It was observed that the mean zinc levels were low in 
all children and the supplemented group had a significantly higher zinc level 
after the intervention. 
 
 Low serum zinc levels have been noted commonly in malaria and 
Duggan et al
45
 studied the relation between the acute phase response and 
plasma zinc concentration in a large cohort of children with falciparum malaria. 
They noted that the predictors of admission levels of serum zinc were the 
admission levels of C-reactive protein (which is a marker of the acute phase 
response), the parasite density and the study site. These factors affected the 
changes in plasma zinc concentration also. 
 
Conclusion - Efficacy of zinc in malaria 
 There is no significant statistical evidence to show that zinc 
supplementation affects the course of illness when used in the treatment of 
malaria. This statement is based only on the currently available data. 
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Therapeutic zinc supplementation as an adjunct in the treatment of 
children with tuberculosis 
 An extensive literature search did not identify any randomised 
controlled trials evaluating the benefits of zinc as an adjunct in the treatment of 
children with tuberculosis. 
 
 Studies have been done in adults, however. In a study from India,
46
 15 
patients with pulmonary tuberculosis were supplemented with oral zinc and 
they were compared with 24 patients who did not receive the intervention. The 
patients who received zinc showed an earlier sputum clearance as compared to 
the controls though the difference was not statistically significant. 
 In another study done in adults, in Indonesia,
47
 patients with pulmonary 
tuberculosis received both zinc and vitamin A. They did demonstrate a 
statistically significant higher rate of sputum clearance and radiological 
improvement as compared to the control group. It is unlikely that these results 
could be attributed to zinc alone. 
 
Conclusion - Efficacy of zinc in tuberculosis 
 As yet no randomised controlled studies have been done in children with 
pulmonary tuberculosis to assess the efficacy and benefit of zinc 
supplementation. This is an exciting area for future research. Furthermore, 
studies can be done in children with disseminated tuberculosis and also 
tuberculous meningitis. 
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Summary: 
 To summarise, for the treatment of acute and persistent diarrhoea, zinc 
supplementation  reduces both the duration and severity of diarrhoea especially 
in developing countries. It is possible that these results may be replicated in 
developed countries also but studies have to be done as there is no available 
data. The efficacy of zinc supplementation in infants with diarrhoea needs 
further evaluation. 
  
 As regards pneumonia, evidence of the beneficial effects of zinc, as in 
the case of diarrhoea, are not available. 
  
 Our current knowledge of the mechanisms of action of zinc in these 
infections is limited but there is ample evidence to show that it is beneficial. It 
is of importance in the low income countries where the burden of infectious 
disease is high and low cost adjuncts are the need of the hour. 
 
Zinc as an adjunct in enteric fever: 
 Zinc as a supplement in the treatment of enteric fever is an as yet 
unexplored but exciting option. This is because it has immunomodulatory, 
antioxidant and anti-inflammatory properties. If found to be effective in 
causing an early defervescence, the implications in terms of reduced burden of 
disease, reduction in loss of work days, reduced school absenteeism and 
reduction in costs, both to parents and hospitals, are enormous. It is also very 
cost effective. 
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RATIONALE FOR THE STUDY 
 Zinc is a micronutrient that plays a major role in immune regulation.
38, 48
 
It has been seen that deficiency states may predispose to infections. This may 
be either due to a pre-existing deficiency or due to infection induced 
deficiency.
38
 Zinc deficiency is more often seen in developing countries due to 
malnutrition and a diet lacking in animal protein.
16
 This is further compounded 
by the fact that zinc is not stored in the human body. 
 
 It has been proven that supplementation of zinc definitely has a 
beneficial role in the early recovery from and reduction in severity of 
diarrhoeal disorders i.e. both acute and persistent diarrhoea, and shigellosis.
7
 
The putative mechanism by which zinc acts in diarrhoea is by a direct effect on 
the intestinal mucosa and a gut associated immune response.
7, 20
 In this context, 
this study was planned to ascertain the possible benefits of zinc 
supplementation in enteric fever, as it is also primarily an intestinal infection. 
Furthermore, many studies involving the use of zinc in infections have been 
done in children less than five years of age.
7, 27, 29, 30
 Hence, we thought we 
could test out our hypothesis by supplementing higher doses of zinc along with 
antibiotic therapy, for a week, in older children with enteric fever. If found to 
be beneficial, it could have enormous public health implications. 
             
 We would like to acknowledge Dr. Christa L Fischer Walker and Dr. 
Robert E Black from the Department of International Health, Johns Hopkins 
Bloomberg School of Public Health, Baltimore, USA. It was from their paper 
in the Lancet, in 2012, that we got the idea to do this research.
49 
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MATERIALS AND METHODS 
 
Study design: 
Prospective, randomized, double blind, placebo controlled study. 
 
Place of study: 
Inpatient ward, Department of Paediatrics 
ESIC Medical College & PGIMSR, K. K Nagar, Chennai. 
 
Period of study: 
November 2014 – August 2016. 
 
Sample size: 
Thirty-two each in the treatment arm and control arm 
 
Target sample size calculation: 
 In order to estimate a 25% reduction by zinc in the time taken for 
defervescence of fever, in enteric fever, between the intervention and control 
groups for a 95% confidence level and 80% power, the sample size was 
calculated to be 32 in each arm.  
 
 N = 2×SD
2
 / d
2
 [Where N – sample size, SD – standard deviation of time 
taken for defervescence of fever (1 day), d – required  (25%) reduction in time 
taken for defervescence]. (Reference - Whitley, Elise, and Jonathan Ball. 
"Statistics review 4: sample size calculations." Critical care 6.4(2002):1.)  
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Study population: 
 The study population included all paediatric ward patients less than 12 
years of age with proven enteric fever. 
 
Inclusion Criteria: 
Children admitted to the paediatric ward with fever (>100.4 ºC) and 
Salmonella typhi or  paratyphi grown in blood culture  
(or) 
Blood widal suggestive of enteric fever (O antigen titre > 1:160)  
(or) 
Four-fold rise in titre of blood widal (a minimum gap of 1 week between two 
samples) 
 
Exclusion Criteria: 
 Lack of parental consent 
 Children with enteric fever who were on inotropes 
 Children with enteric fever with no response to IV ceftriaxone even after 
10 days of therapy 
 Children with enteric fever who presented with intestinal complications 
i.e. perforation 
 
Procedure: 
Enrolment started as soon as approval from the IRB was obtained. 
For all the children who presented with fever, a detailed history was taken and 
a thorough clinical examination was done. The baseline details were recorded 
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in a proforma. After obtaining a written informed consent from the parents, 
complete blood counts, Widal test, and blood culture and sensitivity was done. 
In addition, smear for malarial parasite (MP), Dengue serology, and urine 
culture and sensitivity were done to rule out other causes of fever. 
 
Investigations 
 For complete blood counts and smear, 1 ml of blood was collected in an 
EDTA container and sent to the pathology laboratory. Complete blood count 
was done by an automated cell counter and the peripheral smear was verified 
by the pathologist.  
 
EDTA container 
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5-part cell counter 
 
 
Widal test 
 Widal test is used for the measurement of H and O agglutinins in the 
patient’s sera. There are two methods for detection of agglutination i.e. the tube 
and slide agglutination method. In our study, the tube agglutination method 
was performed.  
 
Widal test - tube agglutination method 
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 2 ml of blood was collected in a serum container and sent to the 
microbiology laboratory. Equal volumes of serial dilutions of the serum from 
1/10 to 1/640 and antigens H and O (prepared using Salmonella typhi 901 
strain) were mixed in the tubes and incubated overnight in a water bath at 37 
°C. Control tubes with antigen and normal saline were set and the agglutination 
titres were read. Agglutinins usually appear by the end of the first week in 
enteric fever and steadily increase till the third or fourth week, after which they 
decline. Demonstration of a rise in titre is more meaningful than a single test. A 
titre is said to be significant if it is 100 or more for the O antigen and 200 or 
more for the H antigen. 
  
 In many developing countries the titre is taken as significant if it is equal 
to or more than 1 in 160 dilutions for O and H agglutinins. In our study we 
have used this cut off for the titre. 
 
Blood culture and sensitivity 
 Under strict aseptic precautions, 2ml blood was drawn and inoculated 
immediately into the blood culture bottle. The bottle was sent immediately to 
the microbiology laboratory and incubated at 37° C. This was subsequently sub 
cultured on Mac Conkey agar. Pale non-lactose fermenting colonies that 
appeared on this medium were picked for biochemical tests like gas formation, 
turbidity after one, two and three days. If there was no evidence of growth even 
after 72 hours, the culture was reported as sterile.  
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Blood culture bottle 
 
Incubator 
 
 
Antibiotic sensitivity testing 
 After detection of the organism, antibiotic sensitivity was tested for 
using the Kirby-Baur technique in Muller-Hinton agar. Antibiotic discs were 
plated and incubated for 24 hours at 37 ºC. Subsequently, the zone of inhibition 
was measured and results were interpreted.  
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Drug sensitivity testing 
 
 
Dengue Serology 
 For dengue serology, 2 ml of blood was collected in a serum container 
and the labelled sample sent to the microbiology laboratory. NS1 antigen and 
anti-dengue antibodies (IgM and IgG capture enzyme commercial 
immunoassays) detection was done and reported. 
 
Container for serology test 
 
Urine culture and sensitivity 
 Urine culture was done to rule out urinary tract infection. Mid-stream 
clean catch sample was collected in a sterile container and sent to the 
microbiology laboratory immediately. Report was obtained after 48 hours.  
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Container for urine culture 
 
 
 Once investigation results were obtained, only proven cases of typhoid 
fever (positive Widal test or blood culture positive for Salmonella species) 
were selected. After obtaining informed written consent from the parent, 
children were recruited into this study. All clinical findings, investigations, 
treatment details, and response to treatment were documented in a pre-
structured study proforma. 
 
Method of randomization: Simple randomization 
Method of allocation concealment: Using sealed envelopes 
Blinding and masking: Blinding of key investigator, participants and 
statistician 
 Sixty four sealed envelopes (32 zinc and 32 placebo) were made. All 
proven enteric fever cases were divided into two groups (zinc or placebo) by 
lots method (Randomization).  
  
 Assignation of patients to either the zinc or placebo group was based on 
chance alone. This minimized the differences among groups by equally 
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distributing children with particular characteristics among all the groups. 
Randomization also eliminated the selection bias. 
 
Intervention: 
 Intravenous access was obtained, for every child included in the study, 
under strict aseptic precautions. Both groups were treated with Inj. Ceftriaxone 
75 mg/kg/day in two divided doses intravenously until 5 days after 
defervescence of fever or for a total of 10 days, whichever was earlier. One 
group was given tablet zinc 40 mg (children > 6 months) or 20 mg (children < 
6 months) once daily as powdered sachets without label and the other group 
was given placebo as powdered sachets without label (double blinding) for 7 
days along with IV antibiotics. Oral zinc and placebo were both administered 
as powders in sachets and they were similar in colour, smell and taste. Patients 
in the zinc group received elemental zinc in the form of zinc sulphate. 
  
 All the sachets were given by the principal investigator daily to the 
parent and the parent was instructed to administer it to the child in his presence. 
In the event of vomiting the dose was repeated. Intravenous antibiotic and oral 
zinc/ placebo were started on the same day. Monitoring for side effects due to 
the drugs was done meticulously. 
 
Data Safety Monitoring Board (DSMB) 
 Adverse effects due to zinc or the placebo used were thought to be 
unlikely therefore DSMB clearance was not obtained. 
 
50 
 
Ceftriaxone vial used in the study: 
 
 
Powder containing sachet 
 
Monitoring: 
 The enrolled children were examined daily and monitored for clinical 
improvement and also complications. Daily monitoring of vitals and systemic 
examination was done. The outcomes observed for were the time taken for 
resolution of toxemia (subjective) and defervescence of fever (objective) after 
starting therapy. Upon completion of intravenous therapy and defervescence of 
fever, the child was discharged on oral antibiotics to complete a 14-day course.  
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 A single observer namely the principal investigator monitored all the 
patients through the entire course of the study. 
 
Algorithm of the study:  
 
 
 
 
 
 
 
 
 
 
Enrolment into the study (Children 
aged 1-12 years with enteric fever 
proved by Widal or culture)
Total sample n=64
Baseline assessment of Hb, Total 
count, platelet count
Randomisation into two groups (32 each)
32 cases who will receive 
placebo for one week 
32 cases who will receive 
zinc supplementation (40 
mg/ day for one week) 
Assessment of primary outcome i.e. time 
taken for defervescence of fever and 
resolution of toxemia in the two groups 
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Study outcomes: 
Primary outcomes – Time taken for defervescence of fever and resolution of 
toxemia in both groups. 
Secondary outcome – Duration of hospital stay after start of intervention in 
both groups. 
 
Statistical Analysis:  
 Descriptive and inferential statistical analysis was carried out in the 
present study. Results of continuous measurements were presented as Mean  
SD (Min-Max) and results of categorical measurements were presented as 
Numbers (%). Significance was assessed at 5 % level of significance. The 
following assumptions on data were made. 
1. Dependent variables should be normally distributed,  
2. Samples drawn from the population should be random, cases of the 
samples should be independent. 
 Student t test (two tailed, independent) was used to find the significance 
of study parameters on continuous scale between two groups (Inter group 
analysis) on metric parameters.  
  
 We used Kaplan-Meier survival analysis to compare differences in the 
time to resolution of toxemia and defervescence of fever between the two 
groups and the log-rank test to test for significance. We analysed the 
probability of having toxemia and fever on an intention to treat basis, including 
all patients assigned to the study. We analysed outcome variables (resolution of 
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toxemia & defervescence of fever) only for patients who completed the study. 
Log-rank test was done to assess significance level. 
 Chi-square/ Fisher Exact test was used to find the significance of study 
parameters on categorical scale between two or more groups.  
 
Significant figures  
+ Suggestive significance (P value: 0.05<P<0.10) 
* Moderately significant (P value: 0.01<P  0.05) 
** Strongly significant (P value: P0.01) 
  
Statistical software: The Statistical software namely SAS 9.2, SPSS 15.0, 
Stata 10.1, MedCalc 9.0.1, Systat 12.0 and R environment ver.2.11.1 were used 
for the analysis of the data. Microsoft word and Excel were used to generate 
graphs, tables etc. 
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Results 
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RESULTS 
 This study was done between November 2014 and August 2016. A total 
of 58 enteric fever cases were found eligible for recruitment and were enrolled 
in this prospective, randomized, double blind, placebo controlled study. They 
were randomized into two arms of 29 each. Analysis was done for all these 
patients as there were no drop outs. 
 
Table 1: Baseline characteristics of the study population. 
Characteristics 
Zinc group 
(n=29) 
Placebo group 
(n=29) 
P 
value 
Age (years) 6.48±3.15 7.55±2.59 0.163 
Sex (Male + Female) (15 + 14) (15 + 14) 1.000 
Weight (kg) 18.21±5.71 19.76±5.36 0.291 
Height (cm) 111.93±15.76 117.62±13.42 0.144 
Duration of fever at admission 
(days) 
7.48±3.66 6.72±3.47 0.422 
Widal positive  13(44.8%) 11(37.9%) 0.594 
Culture positive 19(65.5%) 22(75.9%) 0.387 
Time taken for diagnosis from 
onset of fever (days) 
9.76±2.87 9.17±3.23 0.468 
Time taken for diagnosis from 
admission (days) 
2.24±1.57 2.45±1.30 0.587 
Number of children with toxemia 20 (69%) 23 (79.3%) 0.368 
Duration of therapy (days) 7.76±1.15 8.28±1.67 0.175 
Out of 58, children 67% were above 5 years of age. 
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Algorithm of the study: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Admission of suspected enteric fever cases  
Investigations to confirm diagnosis (Widal &blood 
culture) 
Assessed for eligibility n=58 
58 enrolled after written informed consent 
 Lost to follow-up 
(n=0) 
 Discontinued 
intervention (n=0) 
 Complications due to 
disease (n=0) 
 Complications due to 
intervention (n=0) 
 Absconded (n=0) 
 
 Lost to follow-up 
(n=0) 
 Discontinued 
intervention (n=0) 
 Complications due to 
disease (n=0) 
 Complications due to 
intervention (n=0) 
 Absconded (n=0) 
 
 
Randomization & double blinding 
 
 Allocated to 
intervention (zinc 
group) (n=29)  
 Received allocated 
intervention (n=29)  
 Did not receive 
allocated intervention 
(n=0) 
 Allocated to 
intervention (Control 
group) (n=29) 
 Received allocated 
intervention (n=29) 
 Did not receive 
allocated intervention 
(n=0) 
 
Follow up 
Analysis (n=29) 
Excluded from analysis (n=0) 
Analysis (n=29) 
Excluded from analysis (n=0) 
 
Analysis 
Results 
Allocation 
57 
 
Demographic characteristics of supplementation and placebo groups. 
Age distribution: 
 Among the 58 participants enrolled in the study, the mean age was 
7.02±2.90 years. Of which 56.9% were in the 6-10 year age group, 32.8% in 
the 1-5 year age group and 10.3% children were >10 years of age. 
  
 Mean age in the treatment (zinc) and control (placebo) groups were 
6.48±3.15 years and 7.55±2.59 years respectively. In the zinc group, about 
41.4% (n=12) cases were between 1-5years, 44.8% (n=13) were between 6-10 
years and 13.8% (n=4) were >10 years of age. In the placebo group, about 
24.1% (n=7) cases were between 1-5 years, 69% (n=20) cases were between 6-
10 years and about 6.9% (n=2) were in the age group of >10 years. 
 
Figure 1: Age distribution among the study population 
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Gender Distribution: 
It was observed that 51.7% (n=30) of the total children were boys and 48.3% 
(n=28) were girls. 
 
 Out of the 29 cases, 51.7% (n=15) were boys and 48.3% (n=14) were 
girls in the zinc group. The same gender distribution was seen in the placebo 
group as well i.e. 51.7% (n=15) were boys and 48.3% (n=14) were girls.  
 
Figure 2: Gender distribution among both groups. 
 
 
Duration of fever at admission: 
 The mean duration of fever among all children, at the time of admission 
was 7.10±3.56 days. In the zinc group it was 7.48±3.66 days and in the P 
placebo group it was 6.72±3.47 days. 
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 In the zinc group, 31% (n=9) cases presented within 6 days of fever, 
58.6% (n=17) cases presented between 6 to 12 days and 10.3% (n=3) cases 
presented between 12-18 days. In the placebo group, 41.4% (n=12) cases 
presented with fever within 6 days, 51.7% (n=15) presented between 6 to 12 
days and 6.9% (n=2) cases had fever between 12 to 18 days at admission. 
 
Figure 3: Duration of fever at admission in two groups (zinc vs placebo) 
 
 
Prior treatment with antibiotics: 
 History of prior treatment with antibiotics was observed in 63.8% of 
total cases (n=37), 43.2% (n=16) of cases in the placebo group and 56.7% 
(n=21) of cases in the zinc group. 
 
 The antibiotics used were either oral amoxicillin, cephalosporins or 
fluoroquinolones. 
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Symptomatology: 
 All the children enrolled in the study presented with fever. In the total 
study population, associated symptoms in decreasing order of frequency were 
anorexia (94.8%), vomiting (51.7%), myalgia (48.3%), constipation (41.4%), 
abdominal pain (36.2%), cough (32.8%), abdominal distention (24.1%), 
diarrhea (20.7%), headache (15.5%) and loss of weight (6.9%). 
          In the treatment group, the predominant symptom associated was 
anorexia (93.1%, n=27) followed by vomiting and myalgia (37.9% each and 
n=11 each). The same order of symptom frequency was noted in the placebo 
group also ie. anorexia (96.6%, n=28), vomiting (65.5%, n=19) and myalgia 
(58.6%, n=17). Vomiting was seen more commonly in the placebo group 
(65.5%, n=19), when compared to the zinc group.  
 
Figure 4: Clinical features among the study population 
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Table 2: GI symptoms (Vomiting, abdominal pain, diarrhea & 
constipation) among both groups 
GI symptoms Zinc group (n=29) Placebo group (n=29) 
Yes 19 (66%) 25 (86%) 
No 10 (34%) 4 (14%) 
 
Epidemiological profile: 
 In 15.5% (n=9) of the cases, there was history of another family member 
being affected with typhoid fever at about the same time as the index case 
(44.4% of cases [n=4] in the zinc group and 55.5% [n=5] in the placebo group). 
 
 In the study population only one child had been vaccinated against 
typhoid fever. 
 
 Totally 19% (n=11) of the study population were consuming boiled 
water for drinking. In this 63.6% (n=7) of children were in the zinc group and 
36.4% (n=4) in the placebo group. Sources of drinking water included metro 
water and mineral water.  
 
 In the study population all the children were using a sanitary latrine. 
About 22.4% (n=13) of the study population had eaten outside prior to the 
onset of disease. In this 53.8% (n=7) of the children were in the zinc group and 
46.2% (n=6) were in the placebo group.  
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Figure 5: Epidemiological factors in both groups 
 
 
Clinical signs: 
 On examination, 74.1% (n=43) of children in the study population were 
toxic   at the time of admission. Of this, 69% (n=20) of children were in zinc 
group and 79.3% (n=23) were in placebo group.  
 
 Only one child was dehydrated at the time of admission. Sixty percent 
(n=35) of the study population had coated tongue at presentation. Of this, 
48.6% (n=17) of children were in the zinc group and 51.4% (n=18) were in the 
placebo group.  
 
 In the study population, 56.9% (n=33) of children had pallor at 
admission. 51.7% (n=15) of children in the zinc group and 62.1% (n=18) of 
children in the placebo group were pale.  
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 58.6% (n=34) of the total study population had generalized 
lymphadenopathy at admission (62.1% [n=18] of children in the zinc group and 
55.2% [n=16] in the placebo group). In most cases, cervical and axillary lymph 
nodes were enlarged. 
 
Figure 6: General examination findings among the study population 
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12.1% (n=7) of the study population had high grade fever at the time of 
admission, of which 17.2% (n=5) were in the placebo group and 6.9% (n=2) in 
the zinc group.  
 
Figure 7: Grading of fever in the study population (Low grade – 100.4 to 
102ºF, Moderate grade – 102 to 104ºF, High grade - >104ºF) 
 
 
Table 3: Temperature in the two groups studied 
Temperature Zinc group Placebo group Total 
Low grade 8(27.6%) 4(13.8%) 12(20.7%) 
Moderate grade 19(65.5%) 20(69%) 39(67.2%) 
High grade 2(6.9%) 5(17.2%) 7(12.1%) 
Total 29(100%) 29(100%) 58(100%) 
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 In the study population, the most common finding seen on examination 
of the abdomen was hepatomegaly 93.1% (n=54). Hepatomegaly was seen in 
96.6% (n=28) of the children in zinc group and 89.7% (n=26) in the placebo 
group. Splenomegaly was seen in 75.9% (n=44) of the study population. 79.3% 
(n=23) of the children in zinc group and 72.4% (n=21) in placebo group had 
splenomegaly at the time of admission. Tympanitic note on percussion of the 
abdomen was present in 70.7% (n=41) of the total study population at the time 
of admission, 72.4% (n=21) in the zinc group and 69% (n=20) in the placebo 
group.     
 
Figure 8: Findings on abdomen examination in both groups. 
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Investigations: 
Complete Blood Count: 
 Total leucocyte count was normal in 82.8% (n=48) cases, with 
leukocytosis observed in 10.3% (n=6) cases and leucopenia observed in only 
6.9% (n=4) cases. 
 
Figure 9: Total leucocyte count (cells/ cu mm) in both groups. 
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 Hemoglobin levels were below 12 g/dL in 86.2% (n=50) of the study 
population. In the zinc group, 89.7% (n=26) of the children had a hemoglobin 
level of less than 12 g/dL and in the placebo group 82.8% (n=24) of the 
children had a hemoglobin of less than 12g/dL. 
 
 
Figure 10: Hemoglobin levels in the study population 
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 In 77.6% (n=45) of the total study population the platelet count was 
normal. Thrombocytopenia was observed in 12.1% (n=7) of the total study 
population with 6.9% (n=2) in the zinc group and 17.2% (n=5) in the placebo 
group. 
 
Figure 11: Platelet counts (cells/cu mm) in the study population. 
 
 
Table 4: The mean values and SD of hemoglobin, total WBC count and 
platelet count in both the groups is listed below in the table. 
Variables Zinc group Placebo group Total P value 
Hemoglobin 
(g/dl) 
10.53±0.98 10.87±0.95 10.70±0.97 0.189 
WBC Count 
(per cu mm) 
8468.97±4419.4 6624.14±2710.3 7546.55±3750.8 0.060+ 
Platelet 
Count 
(per cu mm) 
261965.52±114222.1 215517.24±69001.9 238741.38±96418.8 0.066+ 
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 Blood widal was positive in 41.4% (n=24) of children in the study 
population, 44.8% (n=13) of children in the zinc group and 37.9% (n=11) in the 
placebo group.  
 
 70.7% (n=41) of the study population grew enteric bacilli in blood 
culture. 65.5% (n=19) were from the zinc group and 75.9% (n=22) from the 
placebo group.   
 
Figure 12: Widal test positivity in the zinc group 
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Figure 13: Widal test positivity in the placebo group 
 
 
Figure 14: Blood culture growth in the study population 
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Mean duration of diagnosis from admission: 
 The mean time taken for arriving at the diagnosis in the zinc group was 
2.24±1.57 days and 2.45±1.30 days in the placebo group. 
 
Toxemia resolution time: 
 The mean toxemia resolution time after intervention in the zinc group 
was 1.45±1.18 days and in the placebo group was 2.00±1.22 days. Mean time 
for resolution of toxemia was half a day earlier (13 hours) for the zinc group 
than for placebo. Fifty eight percent (n=25/43) of the study population showed 
resolution of toxemia within 2 days. Seventy five percent (n=15/20) of children 
in zinc group and 43% (n=10/23) in the placebo group showed resolution of 
toxemia within 2 days.  
 
Table 5:Toxemia resolution in both the groups. 
Time taken for 
resolution of toxemia 
(Days) 
Zinc group 
(n=20) 
Placebo group 
(n=23) 
Total 
(n=43) 
1 day 4 (66.7%) 2 (33.3%) 6 (100%) 
2 days 11 (57.9%) 8 (42.1%) 19 (100%) 
3 days 4 (25%) 12 (75%) 16 (100%) 
4 days 1 (50%) 1 (50%) 2 (100%) 
Total 20 (46.5%) 23 (53.5%) 43 (100%) 
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Figure 15: Toxemia resolution (days) in both the groups. 
 
 
 
Figure 16: Probability of having toxemia by day of intervention. X-axis: 
Resolution of toxemia (days), Y-axis: Proportion of patients (Cumulative 
survival). Kaplan-Meier survival curve in intention to treat analysis, 
showing recovery from toxemia in zinc supplemented group (n=20) and 
placebo group (n=23). 
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 In the intention to treat analysis, the proportion of children who 
clinically recovered from toxemia by day 2 (15 (75%) v 10 (43%), P=0.054) 
was higher in the zinc supplemented children. 
 
Defervescence of fever: 
 The mean fever resolution time in zinc group was 2.83±1.31 days and in 
placebo group it was 3.69±2.21 days. Mean time for defervescence of fever 
was about one day (21 hours) earlier for the zinc group than for the placebo 
group.  
 
 Approximately sixty four percent (n=37) of the study population showed 
defervescence of fever within 3 days. Seventy six percent (n=22) of children in 
zinc group and 51.7% (n=15) in placebo group showed defervescence of fever 
within 3 days. Maximum time taken for defervescence was 6 days in the 
treatment arm and 8 days in the control arm. In 90% cases in the treatment arm, 
fever resolved by the fourth day while only 59% cases in the control arm 
became afebrile by the fourth day. 
 
Figure 17: Defervescence of fever in both groups. 
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Figure 18: Probability of having fever by day of intervention.  X-axis: 
Defervescence of fever, Y-axis: Proportion of patients (Cumulative 
survival). Kaplan-Meier survival curve in intention to treat analysis, 
showing recovery from fever in zinc supplemented group (n=29) and 
placebo group (n=29). Median recovery was 2 days in zinc supplemented 
group and 3 days in placebo group (P=0.043).  
  
 In the intention to treat analysis, the proportions of children who 
clinically recovered from enteric fever by day 3 (22 (75.9%) v 15 (51.7%), 
P=0.043) and by day 4 (26 (89.7%) v 17 (58.6%), P=0.043) were significantly 
higher in the zinc supplemented children. The median time until recovery was 
shorter among the zinc supplemented children than among the children in the 
control group (2 v 3 days, P=0.043). 
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Total duration of Hospital stay: 
 The mean duration of hospital stay in the zinc group was 10.31±2.21 
days and in the placebo group was 11.17±2.32. The p value obtained on 
comparing the two groups with respect to duration of hospital stay was 0.152 
which is not significant. Children in the placebo arm stayed a day longer in 
hospital (21 hours) as compared to the intervention group. The extra day of 
hospitalization seen in the placebo group is reflective of the extra day taken for 
defervescence seen in the same group. 
 
Figure 19: Total duration of hospital stay among both the groups 
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Duration of hospital stay after intervention: 
 
Figure 20: Probability of discharge by day of intervention.  X-axis: 
Duration of hospital stay (days), Y-axis: Proportion of patients 
(Cumulative survival). Kaplan-Meier analysis, showing hospital stay after 
intervention in zinc supplemented group (n=29) and placebo group (n=29). 
Median duration of hospital stay was around 7 days in zinc supplemented 
group and 8 days in placebo group (P=0.054).  
 
 In the intention to treat analysis, the proportions of children who were 
discharged by day 8 (22 (75.9%) v 15 (51.7%), P=0.054) and by day 9 (26 
(89.7%) v 17 (58.6%), P=0.054) were higher in the zinc supplemented children.  
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Analysis of Primary Objective: 
 On applying the Null hypothesis that oral zinc when used as an adjunct 
along with standard treatment will cause defervescence in enteric fever, the p 
value obtained with respect to fever defervescence, toxemia resolution and 
duration of hospital stay after start of intervention were 0.043, 0.054 and 0.054. 
Hence the Null hypothesis is accepted. This implies that oral zinc did cause an 
early defervescence of enteric fever when used as an adjunct as compared to 
placebo. 
 Therefore oral zinc may be useful as an adjunct in the treatment of 
enteric fever, though larger and better studies are needed before one can 
recommend its use. 
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Discussion 
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DISCUSSION 
 
 We enrolled 58 children who were admitted to the paediatric ward with 
enteric fever. The diagnosis of enteric fever was confirmed based on either a 
positive Widal (17/58)/ blood culture (41/58) or both (7/58). 
 
 In our study, we observed a statistically and clinically significant 
reduction in the time taken for defervescence of fever (p=0.043) in the zinc 
treatment as compared to the placebo group. We also observed a clinically 
significant reduction in the time taken for resolution of toxaemia (p=0.054) and 
in the duration of hospital stay (p=0.054) after start of intervention. Our study 
has, for the first time, indicated that zinc supplementation may have benefits 
over and above antibiotic use in an older cohort of children with enteric fever.  
           
 What we observed was a trend towards earlier resolution of toxaemia 
and fever defervescence in the group with zinc supplementation. Resolution of 
toxaemia was seen within 48 hours in 15/20 (75%) of cases in the zinc 
supplemented group versus only 10/23 (43%) in the control group (p=0.056). 
As regards fever defervescence, by the third day almost 22/29 (76%) of cases 
in the treatment arm had defervesced as compared to only 15/29 (51%) in the 
placebo arm (p=0.04). This proportion increased to 90% (26/29) in the 
treatment arm but only 59% (17/29) in the control arm by the fourth day.  
  
 The duration of hospital stay was not significantly different between the 
two groups. This may be due to multiple reasons – some children were 
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admitted after confirmation of the diagnosis as an outpatient. In them the 
hospital stay was shorter. A few children got admitted over the weekend and 
this resulted in a delay in diagnosis and hence longer hospital stay. In some 
cases, soon after a child was started on treatment for enteric fever, his/ her 
sibling would be admitted a few days later, thereby delaying the discharge. 
             
 We analysed the hospital stay after start of antibiotic therapy and found 
that the proportions of children getting discharged by day 8 (22 (75.9%) v 15 
(51.7%), p=0.054) and day 9 (26 (89.7% v 17 (58.6%), p=0.054) were more in 
the zinc supplemented group. Discharges were made five days after 
defervescence.  
  
 These results are not only statistically significant but also clinically 
significant as any intervention that reduces morbidity and hospitalisation is 
potentially worthwhile especially in children. Earlier recovery and discharge 
would mean fewer school days lost apart from other advantages like less health 
care costs and reduction in disease burden all accruing from a very cost 
effective intervention. The total costs incurred for a week course of oral zinc 
sulphate in this study was only Rs. 56/= (0.73 USD). 
             
 We attempted this randomised control trial as enteric fever continues to 
exist in an endemic form in the Indian subcontinent and despite the 
development of newer and more powerful antibiotics, we are faced with 
widespread and increasing resistance (MDRST, NARST). Therefore, any 
micronutrient, like zinc, that has beneficial effects, would be worth 
investigating as an adjunct in infections. 
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Research idea 
 The research idea for this dissertation was obtained from a paper in the 
Lancet by Dr. Christa L Fischer Walker and Dr. Robert E Black from the 
Department of International Health, Johns Hopkins Bloomberg School of 
Public Health, Baltimore, USA.
49
 In this article, the authors were commenting 
on the promising results obtained by Bhatnagar et al in their study on the 
relative risk reduction in treatment failure due to zinc supplementation in 
infants with serious bacterial infections.
49
 While concluding, they have 
speculated on the potential benefits of zinc, as an adjunct, in enteric fever and 
bacterial meningitis. 
 
 
Concept definition 
 The concept was derived from the fact that in many studies
7
zinc has 
been found to reduce both the severity and duration of infection in diarrhoea 
making its use a recommendation, by the WHO,
7
 along with oral rehydration 
solution (ORS). Other studies like the one by Bhatnagar et al
8
 in which zinc 
was used as an adjunct in the treatment of serious bacterial infections 
(pneumonia, meningitis, sepsis) in infants less than four months of age, and the 
one by Roy et al
28
 in older children with cholera, have both demonstrated 
statistically significant benefits in terms of 40% relative risk reduction for 
treatment failure and in terms of reduction in severity and duration of cholera, 
respectively. 
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 Hence, we decided to study the effects of zinc supplementation in 
enteric fever as the primary site of infection in enteric fever is also the intestine 
from where it disseminates to become a systemic infection. We assumed that 
the mechanisms by which zinc is presumed to act in cases of diarrhoea, cholera 
and serious bacterial infections, would operate in our study too. 
 
Highlights of our study 
 We would like to emphasize the fact that our study is the first of its kind. 
Till date there is no literature to support the use of zinc in enteric fever. Hence, 
we are unable to compare the results obtained in our study with previous 
studies. 
 
 It is also interesting to note that most studies on supplementation of zinc 
in infections have been done in children less than five years of age.
7
 This is 
because zinc deficiency is more common in the under-fives.
5, 28
 There are very 
few studies involving the older age groups. Our study is unique in that aspect 
also as we studied children in the 1 – 12 years age group. The studies by Roy et 
al
28
 and Valery et al,
50
 on the role of zinc supplementation in diarrhoea, were 
done in older children. Similarly, studies on the effect of zinc in pneumonia 
and lower respiratory tract infections, by Mahalanabis et al
42
 and Chang et al,
43
 
have also been done in older children. 
 
 The dosage of zinc used in our study is higher (40 mg/day for children 
more than 6 months of age). Most studies have used 5 – 20 mg/day (ref). This 
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dosing schedule is similar to the studies by Rahman et al
29
 and Roy et al that 
were done in children with shigellosis.  
  
 We used zinc supplementation for a shorter (7 days) but, clearly defined 
duration. This was to ensure standard duration of treatment in both arms and 
also to lessen the incidence of patients lost to follow up or not completing the 
course after discharge. In many studies, zinc supplementation was given only 
until clinical recovery or discharge, making the duration of administration 
variable within the same study.
7 
 
Comparative studies 
 Roy et al found a significant reduction both in the severity and duration 
of cholera in the zinc supplemented group indicating an additional benefit of 
zinc over and above that of the antibiotics.
28
 His cohort of patients belonged to 
a similar age group as ours i.e. 3 – 14 years. They too used higher doses of zinc 
(30 mg/day) but the duration was variable in that supplementation was 
continued only until clinical recovery. 
  
 Our study had similarities with their study in that the proportion of 
children who recovered by day 3 in our study (76% in the zinc group versus 
51% in the placebo group, p=0.04), was striking. In their study, the proportions 
were 75% versus 62% (p=0.024). Another striking observation in our study 
was that by day 4, almost 90% of children in the zinc arm had defervesced 
while only 59% of cases in the control arm had become afebrile. 
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 If one takes into consideration the fact that the longest time taken for all 
children to become afebrile in our study is 8 days, then the fact that 90% of 
zinc supplemented children had become afebrile in half that time is of clinical 
significance. 
  
 In yet another study by Roy et al
27
 in children less than five years of 
age, the role of zinc supplementation was studied in malnourished children 
with shigellosis, which is also a gram negative gut associated infection. They 
too used 20 mg of oral zinc twice a day for two weeks. They observed a 
significant shortening of the duration of acute shigellosis along with additional 
benefits of better weight gain during the recovery period and reduced morbidity 
due to diarrhoea during the subsequent six months. 
 
 Both shigellosis and cholera are gram negative infections primarily 
affecting the gastrointestinal system hence these studies were the closest, in 
terms of microbial characteristics and pathogenesis, to ours. The effects of zinc 
supplementation seen in both these studies by Roy et al may indicate a specific 
benefit with bacterial infections of enteric origin. 
 
 While the sample size in the cholera study was 82 per group, the 
shigellosis study had enrolled 56 children, which makes it comparable to ours.  
The one salient feature of both these studies was that they only recruited cases 
with stool culture having grown vibrio cholerae or shigella species. Isolation of 
the organism by culture remains the gold standard for the diagnosis of 
infections and thus the validity of these two studies increased as a consequence 
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of including only culture positive cases. In our study, although 71% were blood 
culture positive, we did include children with fever and Widal positivity as 
well. Serological diagnosis does have its limitations. Hence, our study could 
have been made stronger by recruiting only blood culture positive cases.  
  
 The study by Bhatnagar et al
8
 was a multicentric one, done at Delhi. It 
is comparable to ours in a few aspects in that they looked at zinc 
supplementation in serious bacterial infections, like pneumonia, meningitis and 
sepsis, in infants, in the setting of a developing country. They used clinical 
criteria as per the IMNCI guidelines for the diagnosis and used CRP, 
procalcitonin and blood culture to segregate the infants with bacterial 
infections. They reported a reduction in treatment failure by 40% though time 
to recovery did not differ significantly between the two groups. 
 
 Haider et al, in their review article on the effect of therapeutic zinc 
supplementation among young children with selected infections, have stated 
that there is substantial evidence to show that zinc supplementation reduces the 
duration of acute diarrhoea by 0.5 day (p=0.002) in children under 5 years of 
age.
7
 In persistent diarrhoea, the duration is reduced by 0.68 day (p < 0.0001). 
In our study, on comparing two groups which were very similar in all aspects 
except for the intervention or the lack of it, fever defervescence, which was the 
stated primary outcome, was significantly earlier in the zinc supplemented 
group (p=0.04). 
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Zinc supplementation – Putative mechanisms of action 
In all these gut associated infections, the exact mechanisms by which zinc acts 
is not yet clearly elucidated. A few putative mechanisms are
7
: 
1. Improved water and electrolyte absorption. 
2. Immunomodulation causing reduction in bacterial proliferation. 
3. Improved mucosal permeability. 
While all these mechanisms may play a role we feel that zinc supplementation 
in enteric fever may act specifically by the following mechanisms
5,13
: 
1. Reduced expression of cytokines (IL 1B, TNF, IL 6) thereby attenuating 
the inflammatory cascade. 
2. Gut associated immune response inhibiting bacterial proliferation. 
3. Antioxidant properties which prevent free radical formation and the 
morbidity thereof. 
4. Promoting proliferation of the intestinal epithelial cells causing healing 
of epithelial injury. 
 
Assessment of serum zinc levels 
 While we could not perform serum zinc levels in our study to assess 
baseline zinc deficiency states, we feel that infection induced zinc deficiency, 
which is a well recognised and documented, though transient 
phenomenon,
5,13,45
 may contribute to morbidity in enteric fever. The beneficial 
effects may be due to correction of this deficiency by supplementation.  
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 In the study by Roy et al
28
 in children with cholera, there was a 
statistically significant increase in the serum zinc levels in the group that 
received zinc supplementation as compared to the control group. 
 
 Baseline serum zinc levels could also be low due to a deficient diet, 
malnutrition, and a high phytate to zinc ratio in the diet which may reduce its 
bioavailability (ref – Mahalanabis 2002). Hence, testing serum zinc levels did 
not seem mandatory for our study, as there are other causes for deficient levels 
besides infections. 
 
Salient symptomatology/ signs in our study 
 Gastrointestinal symptoms were predominant in our study. They were 
third in frequency after fever and myalgia. All gastrointestinal symptoms taken 
together i.e. vomiting, anorexia, constipation, diarrhoea and abdominal pain, 
were seen in 65% (19/29) of the zinc supplemented group and 86% (25/29) in 
the control group. We noted that the children with less gastrointestinal 
manifestations defervesced earlier than those with these symptoms (p=0.096). 
We can only postulate that the children with more gastrointestinal 
manifestations had a more severe infection and hence had a later defervescence 
as compared to the children who had fewer gastrointestinal manifestations. 
Even when we looked at diarrhoea in isolation, we found that children who did 
not have diarrhoea showed an earlier defervescence than the children who 
manifested with diarrhoea, although the numbers were small.  
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 This is at variance with the study by Bhatnagar et al
8
 in which they 
noted that zinc had a greater effect in reducing treatment failures (relative risk 
reduction) in infants with serious bacterial infections who had diarrhoea at 
presentation. They noted that the infants presenting with diarrhoea also had 
lower CRP levels hence may have had milder disease that could explain the 
greater beneficial effect of zinc in them.  
 
 There could be many reasons for this difference namely the age group 
being studied, the type of disease being studied etc. Further studies need to be 
done before one could explain this observation. 
  
 Toxemia was seen in 74% of our study cases in contrast to the study by 
Ganesh et al
51
 where only 16% were toxic. In our study, although a single 
observer was documenting the presence/ absence of toxaemia and its 
resolution, this is a very subjective sign and has the potential to be over 
interpreted. On the other hand, the same observer having done the assessment 
through the entire study period introduces the same amount of subjective bias 
in all the children. 
 
 Most children had moderate grade fever with only 12% presenting with 
high grade fever. 
 
Public health issues highlighted by our study 
 The salient public health issues noted from our study are the potential 
reduction in cost of care, hospital stay, morbidity and burden of disease as a 
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consequence of the early defervescence. A costing study would be able to 
highlight the economic benefit accrued. 
 
 Ram et al
52
 observed that almost 90% of the cases in their study used 
unboiled drinking water as against 81% in our study, thus emphasizing the fact 
that boiling drinking water, especially for children, is a very important aspect 
of food safety. 
 
 It was heartening to note that 100% of the children had access to 
sanitary latrines. 
  
 It was very disheartening to note that only one child had been vaccinated 
against typhoid fever in our study population. This suggests that we, as 
paediatricians, may not be spreading awareness, to an adequate extent, about 
the availability of vaccines against typhoid. But spreading awareness alone 
may not be enough as typhoid vaccination is not part of our National 
Immunisation Schedule. One needs to also look critically at procurement, cold 
chain, delivery and cost coverage mechanisms for uptake of vaccines. 
 
Clinical impact of our study 
 In our study, resolution of toxaemia and defervescence were 
significantly earlier in the zinc supplemented group. This is a very important 
observation for resource poor settings, as in a country like India. Apart from 
the reduction in school absenteeism due to earlier defervescence, beds can be 
made available for other patients and the socioeconomic burden, both to the 
parents and the hospital, can be reduced. 
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 Early resolution of toxaemia would definitely lead to improved appetite 
and an early nutritional recovery. 
 
 Probably the single most important advantage of zinc supplementation, 
apart from the gains in terms of toxaemia, fever defervescence, and hospital 
stay is the fact that it is a very cost effective and safe intervention. 
 
Strengths of our study 
 The strengths of our study are its meticulous randomisation, allocation 
concealment and double blind design. In fact, it was a triple blinding in that the 
primary investigator, the patients and the statistician were blinded. Despite the 
small sample size, there was considerable homogeneity between the two 
groups. 
 
 We would like to state that zinc supplementation may have beneficial 
effects as an adjunct along with antibiotics in the treatment of enteric fever            
and may facilitate an early recovery. But in order to make a strong 
recommendation, larger and better designed studies are needed. 
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Conclusion 
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CONCLUSION 
 
 We would like to conclude that oral zinc, when used as an adjunct along 
with standard antibiotic therapy in children with enteric fever, may cause an 
earlier resolution of toxemia and also an earlier defervescence of fever. This is 
a cost effective and safe intervention. 
 
 This observation needs to be validated in larger studies before it can be 
made into a recommendation. 
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Limitations of the 
Study 
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LIMITATIONS OF THE STUDY 
1. Our study had a small sample size and hence the results need to be 
validated with further studies before a recommendation can be made. A 
larger sample size would have increased the power of the study and 
minimized errors. 
2. Children with fever and widal positivity or blood culture positivity were 
enrolled. In order to increase the internal validity of the study, a uniform 
case definition needs to be used i.e. only blood culture positive cases 
would have increased the internal validity of the study as it is the gold 
standard for the diagnosis of any infection. 
3. We studied only a limited number of clinically relevant outcomes i.e. 
resolution of toxaemia, defervescence of fever and duration of hospital 
stay after start of intervention. 
4. Although there was a single observer, thereby minimizing inter observer 
variability, toxemia was a subjective finding in our study.  
5. Demonstration of microbiological response, by repeating blood culture 
at the end of one week, could not be done due to resource constraints.  
6. Serum zinc levels could not be done in the study population. 
7. This was a single centre study. Multicentric studies could obviate the 
loco regional confounding factors. 
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Directions for Future 
Research 
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DIRECTIONS FOR FUTURE RESEARCH 
1. A larger sample size and a better study design could be used to validate 
the trends seen in our study. 
2. A better study design would be to compare only culture positive cases of 
enteric fever with zinc supplementation and placebo. 
3. Differing doses and duration of zinc supplementation could be studied 
with respect to enteric fever. 
4. Studies comparing efficacy of zinc in children with uncomplicated 
versus enteric fever with complications need to be carried out. 
5. Future studies should look at malnourished versus normally nourished 
children with enteric fever to see if zinc has more beneficial effects in 
the malnourished population. 
6. Studies focusing on discovering the mechanism of action of zinc in 
specific infections, like enteric fever, need to be undertaken. 
7. Studies need to be done in developed countries as well in order to 
compare results with those done in developing ones. 
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ANNEXURE - I 
PROFORMA 
Department of Paediatrics 
ESIC Medical College & PGIMSR, K.K Nagar, Chennai 
 
Name:  
Age:                                                              Sex: 
Address/ Phone number: 
Insurance number: 
Date of admission:                                     Date of discharge: 
Diagnosis: 
History: 
 Fever:                                                               
a. Duration - 
b. Pattern - 
c. Chills/Rigors - 
d. Response to antipyretics - 
 Headache: 
 Myalgia: 
 Altered sensorium: 
 Seizures: 
 Anorexia: 
 Loss of weight: 
 Nausea/Vomiting: 
 Diarrhoea: 
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 Constipation: 
 Abdominal pain: 
 Distension of abdomen: 
 Cough: 
 Breathlessness: 
 High coloured urine/ clay coloured stool: 
 Pruritus: 
Treatment history: 
Typhoid immunisation in the past: 
Examination:  
 Toxic/ not: 
 Temperature: 
 Hydration: 
 Coated tongue/ glossitis/ cheilitis: 
 Icterus/ pallor: 
 Vitals (PR, RR, BP): 
 Skin: 
 Lymphadenopathy: 
 CVS: 
 RS: 
 Abdomen: 
a. Distension - 
b. Tenderness - 
c. Hepatomegaly/ tender liver & span - 
d. Splenomegaly & consistency - 
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e. Fluid/ tympanitic note - 
f. Bowel sounds - 
 CNS: 
 Others: 
Anthropometry:    Weight -                           Height -                               MAC – 
Nutritional status: 
Family & Socioeconomic history: 
 Any other member/ sibling affected: 
 Anyone in the neighbourhood: 
 Water supply (Potable/not): 
 Boiled / not: 
 Hand hygiene: 
 Sanitary latrine: 
 Immunisation (Typhoid): 
 Diet (Salads/eating out): 
Complications (if any): 
Investigations: 
 Hb:      
 TC: 
 DC: 
 Smear: 
 Platelet count: 
 Widal:  
 Blood culture: 
 Sensitivity pattern: 
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 Urine culture: 
 Stool culture: 
 LFT: 
 Serum zinc levels: 
 Ultrasound abdomen/ chest: 
 Bone marrow culture: 
 Others (Leptospira, Dengue serology): 
 Mean duration at diagnosis from: 
- Onset of fever 
- After admission 
Treatment given: 
 Medication, route & dose: 
 Duration of therapy: 
Time taken for response after starting antibiotic: 
 Toxaemia: 
 Fever: 
Duration of hospital stay: 
Day of defervescence of fever  
 From onset of fever 
 After starting antibiotics 
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ANNEXURE - II 
PATIENT CONSENT FORM 
 
Study title:  
“Oral zinc as an adjunct in the treatment of Enteric fever” 
 
Study centre:  Department of Paediatrics, ESIC Medical College & PGIMSR, 
K. K. Nagar, Chennai 
 
Participant name:                                            Age:             Sex:          I.P. No   
  
  I confirm that I have understood the purpose of procedure for the above 
study. I have had the opportunity to clarify all my queries and doubts and they 
have been answered to my satisfaction. 
  
 Investigator explained very well about the procedure and I am made 
aware of the safety, advantages and disadvantages of the technique. 
   
 I understand that my participation in the study is purely voluntary and 
that I am free to withdraw at any time without giving any reason. 
  
  I have understood that the investigator, regulatory authorities and the 
ethics committee will have access to my health records both in respect to 
current study and any further research that may be conducted in relation to it, 
even if I decide to withdraw from the study.  
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 I have understood that my identity will not be revealed in anyway and 
information released to third parties or published, unless as required under the 
law. I agree not to restrict the use of any data or results that arise from the 
study.  
 
          Without any compulsion I am willing to give consent for the 
participation of my child in this study. 
 
 
Date:                                        Signature / thumb impression of patient  
Place:         
                                                                                          Patient name: 
Signature of the investigator: 
Name of the investigator: 
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ஆய்வில்பங்கேற்பதற்க்ோனஒப்புதல்படிவம் 
நான்______________________ தகலல் படிலத்தில் இருந்த தகலல்களர படித்து 
அமிந்ததன்/ படிக்க தகட்டமிந்ததன். எனக்கு ககாடுத்த தகலல்களரயும் படித்து புரிந்து 
ககாண்தடன். என்னுட஬ சந்ததகங்களர தீர்த்துக் ககாள்ர எனக்கு 
லாய்ப்பரிக்கப்பட்டது. எனது தகள்லிகளுக்கு  திருப்தி அரிக்கும்  லளக஬ில் பதில்கள் 
லறங்கப்பட்டன. எனது குறந்ளத "ஸிங்க் ஫ாத்திள஭ள஬ ஆன்டிளபத஬ாடிக்குடன் 
கூடுதல் ஫ருந்தாக ளடஃபாய்டு காய்ச்சலில் ப஬ன்படுத்துதல்". என்ம ஆய்லில் கயந்து 
ககாள்ர எவ்லித த஬க்கமும் லற்புறுத்தலும் இல்யா஫ல் முழு஫னத்துடன் ஒப்புதல் 
அரிக்கிதமன் 
1. ஒப்புதல்படிலம்எனக்குலிரக்கிகூமப்பட்டது 
2. இந்தஆய்வுமுளமகுமித்துஎனக்குலிரக்கிகூமப்பட்டது  
3. என்உரிள஫கள்஫ற்றும்கபாறுப்புகளரஆய்லாரர்எனக்குலிரக்கிகூமி஬
ளதபுரிந்துககாண்தடன் 
4. இந்த ஆய்வு பாதுகாப்பானது என்பளத  புரிந்து ககாண்தடன் 
5. நான் தற்தபாது தலறு எந்த ஒரு ஆய்லிலும் பங்தகற்கலில்ளய என்று 
உறுதி அரிக்கிதமன் 
6. இந்த ஆய்லில் இருந்து லியகுலதால் எனது குறந்ளத஬ின் சிகிச்ளசக்கு 
எவ்லித  பாதிப்பும் ல஭ாது என்பளத அமிதலன்  
7. இந்த ஆய்லின் இறுதி஬ில் கிளடக்கும் தகலல்களர ஆய்லாரர் 
உ஬ர்஫ட்ட குழுலினர்க்குத் கதரி஬ படுத்துலளதயும் உள்஫ருத்துல 
இதறில் கலரி஬ிடவும் அனு஫திக்கிதமன்  
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8. தகலல்கள் பதிவு கசய்஬ப்படும் கபாழுது எனது குறந்ளத஬ின் கப஬ர் 
஭கசி஬஫ாக ளலக்கப்படும் என்பளத அமிதலன் 
9. இந்த ஆய்லில் எனது குறந்ளத பங்தகற்க நான் முழு஫னதுடன் 
சம்஫திக்கிதமன்   
 
பங்தகற்பாரரின்கப஬ர்: ____________________________ 
பங்தகற்பாரரின்ளகக஬ாப்பம்: _____________________ 
தததி: 
 
படிப்பமிலில்யாதலர் எனில் பங்தகற்பாரருக்கு தகலல் படிலம் கதரிலாக 
படித்து காண்பிக்கப்பட்டது ஫ற்றும் அலருக்குரி஬  சந்ததகங்களுக்கு லிரக்கம் 
தகட்க லாய்ப்பரிக்கப்பட்டது என்பதற்கு நான் சாட்சி஬ம் அரிக்கிதமன். 
பங்தகற்பாரர் முழுசுதந்தி஭த்துடன் சம்஫தம் கதரிலித்தார் என்பளத உறுதி 
கசய்கிதமன்  
தததி: 
 
பங்தகற்பாரரின் இடதுளக கபருலி஭ல் பதிவு________________ 
சாட்சி ளகக஬ாப்பம்________________________________ 
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ANNEXURE - III 
INFORMATION TO PARTICIPANTS 
Investigator: Dr. Ramakrishnan A. P 
Study centre: Department of Paediatrics, ESIC Medical College & PGIMSR, 
K. K. Nagar, Chennai 
Title: “Oral zinc as an adjunct in the treatment of Enteric fever” 
You are invited to take part in this research study. We have got approval from 
the IEC. You are asked to participate because you satisfy the eligibility criteria. 
 
Aim:  
Rights and confidentiality: 
       The participation in this study is purely voluntary. You have every right 
not to participate in this study and in the event you decide not to, the child will 
get the normal appropriate treatment as before and will not be disadvantaged in 
anyway. All the data collected in this regard from your child and mother will 
be kept discretely and your/child’s name will not be revealed under any 
circumstance. 
Procedure: 
To whom you may contact? 
     If you have any doubts and clarification required you can call the doctor, 
Ramakrishnan A.P at the mobile number 9047939957 at any time. 
Signature / Thumb Impression of Patient 
Patient Name: 
Signature of the Investigator : _______________ 
Name of the Investigator : _______________ 
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1 Zinc 7 2 2 17 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 19 118 108 18 100/60 2 2 1 1 1 9.6 7700 42/51/6/1 173000 1 2 18 1 7 0 2 9 
2 Placebo 8 1 2 7 2 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 1 1 1 1 1 2 2 2 1 2 2 18 124 109 24 100/60 2 2 2 1 2 12.8 7000 62/33/4/1 189000 1 2 11 4 10 3 6 15 
3 Zinc 3 2 1 7 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2 2 1 2 2 12 96 102 30 92/58 1 2 1 2 1 9.8 7000 57/37/6/0 163000 1 1 9 2 7 1 2 10 
4 Zinc 6 2 1 5 2 2 2 2 1 2 2 2 1 2 1 2 1 2 2 2 2 2 1 1 2 1 1 2 2 2 2 2 2 15 108 105 24 100/60 1 2 1 1 1 10.8 7700 81/16/3/0 199000 2 1 7 2 7 1 2 10 
5 Zinc 3 1 1 7 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 1 1 1 2 2 1 1 2 1 1 2 1 14 94 110 34 90/60 1 2 1 1 1 10 9300 49/43/6/2 285000 1 1 9 2 7 2 2 10 
6 Zinc 3 2 2 10 2 2 2 2 1 2 1 2 2 2 1 2 2 2 2 2 2 1 1 1 2 2 2 2 2 1 2 2 1 14 93 102 40 90/60 2 2 1 1 2 8.6 27400 63/32/4/1 539000 1 2 11 1 8 0 3 9 
7 Placebo 7 2 1 8 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 1 14 107 106 24 94/60 2 2 1 1 2 11 7600 54/37/8/1 280000 1 1 8 0 7 0 2 7 
8 Zinc 7 2 1 8 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2 1 2 2 2 29 115 86 20 98/60 2 2 1 1 2 11.3 7900 51/39/9/1 198000 2 1 9 1 6 0 1 7 
9 Placebo 10 2 1 15 2 2 2 2 1 2 1 2 1 2 1 1 2 2 2 2 2 2 1 1 2 2 1 2 2 1 2 2 2 24 133 126 36 100/60 2 1 1 2 2 11.3 5200 58/35/6/1 131000 1 1 17 2 10 3 6 12 
10 Placebo 4 1 1 5 1 2 2 1 1 2 1 2 1 2 2 1 2 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 20 114 112 28 100/60 2 2 1 1 1 11 7100 60/13/18/9 167000 2 1 8 3 6 1 1 11 
11 Zinc 7 2 1 4 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 1 3 2 2 2 2 1 17 120 122 32 106/60 2 2 1 1 2 12.6 8700 56/35/8/1 205000 2 1 9 5 8 2 3 13 
12 Zinc 5 2 1 8 1 2 2 1 1 2 2 2 1 2 1 2 1 2 2 2 2 1 1 1 2 2 1 2 2 1 1 2 1 18 118 126 30 90/50 1 2 1 1 1 10 5200 51/44/5/0 216000 2 1 12 4 8 2 3 12 
13 Zinc 6 1 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 1 20 120 128 32 100/60 2 2 2 1 2 10.3 7100 59/30/11 336000 2 1 5 3 7 2 2 10 
14 Placebo 7 1 1 3 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2 1 1 2 1 17 116 98 26 96/62 2 2 1 1 2 12.3 7900 77/14/8/1 179000 2 1 6 3 10 3 6 13 
15 Zinc 10 2 2 3 2 2 2 1 1 2 2 2 2 2 1 1 1 2 2 2 2 1 1 1 2 2 1 2 2 1 2 2 2 23 135 118 28 100/70 1 2 1 1 1 11.2 5900 56/36/7/1 184000 1 2 9 6 8 2 3 14 
16 Placebo 5 2 1 6 2 2 2 2 1 1 2 2 1 2 1 2 1 2 2 2 1 2 1 1 2 2 1 3 2 1 1 2 1 13 107 110 28 90/60 1 2 1 1 1 11.2 5100 51/42/7/0 133000 2 1 10 4 10 3 5 14 
17 Placebo 10 2 1 3 1 2 2 1 1 2 2 2 1 2 2 1 1 2 2 2 2 2 1 1 2 1 1 2 2 2 2 2 2 25 130 106 26 100/60 1 2 2 2 1 12.5 6400 82/15/3/0 234000 2 1 6 3 8 1 3 11 
18 Placebo 9 2 2 18 2 2 2 2 1 2 2 2 2 1 2 2 1 2 2 2 1 2 1 1 2 2 1 2 2 1 1 2 2 17 122 98 26 100/60 1 2 1 2 1 10.6 11100 36/55/9/0 414000 1 2 19 1 10 3 5 11 
19 Zinc 3 2 2 12 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 1 1 2 2 1 1 2 1 2 2 2 11 92 96 28 90/60 1 2 1 1 1 12 15100 44/48/8/0 437000 1 2 13 1 9 2 4 11 
20 Placebo 3 1 1 8 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 1 11 96 112 30 90/58 2 2 1 1 1 11.5 12900 36/56/8/0 191000 2 1 13 5 6 0 1 11 
21 Zinc 11 1 1 6 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 1 1 2 1 1 2 2 1 1 2 1 26 129 118 28 110/60 1 1 1 1 1 11 4800 58/36/6/0 321000 2 1 9 3 10 3 6 13 
22 Placebo 12 2 1 10 2 2 2 1 1 2 2 2 2 2 1 1 2 2 2 2 2 2 1 1 2 2 1 2 2 1 1 2 1 25 136 120 36 90/60 1 2 1 1 1 11 6800 60/36/4/0 210000 2 1 13 3 10 3 5 15 
23 Placebo 4 1 1 4 1 2 2 1 1 2 2 2 1 1 2 1 2 2 2 2 2 2 1 1 2 2 1 2 2 1 1 2 1 14 98 120 30 100/60 1 2 1 1 1 10.6 8900 56/34/9/1 263000 2 1 8 4 7 2 2 12 
24 Zinc 7 1 1 6 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 1 1 2 1 2 1 2 2 1 2 1 18 118 123 32 100/60 2 2 1 1 2 11 6400 56/38/5/1 187000 2 1 8 2 6 0 1 8 
25 Zinc 2 1 2 7 2 2 2 2 1 2 2 2 2 2 1 1 1 2 2 2 2 2 1 1 2 2 2 1 2 2 1 2 1 10 85 116 36 92/60 1 2 1 1 1 9.1 8800 35/52/10/3 504000 1 2 10 3 9 0 4 12 
26 Zinc 6 1 1 14 2 2 2 1 1 2 2 2 2 2 1 1 1 2 2 2 2 1 1 1 2 2 1 1 2 1 1 2 1 16 108 98 24 100/60 1 2 1 2 1 11 7900 56/35/8/1 342000 2 1 14 0 8 2 3 8 
27 Zinc 3 2 2 10 2 2 2 2 1 2 2 2 2 2 1 1 2 2 2 2 2 2 1 1 2 1 2 2 2 1 1 2 1 12 95 109 28 100/60 2 2 1 2 1 10.2 15400 41/52/7/0 229000 1 2 11 1 7 0 2 8 
118 
28 Zinc 10 1 2 15 2 2 2 1 1 2 2 2 1 1 2 1 2 2 2 2 1 2 1 1 2 2 1 3 2 1 2 2 1 22 131 110 30 110/60 1 2 1 2 1 10 9400 39/55/6/0 137000 1 2 16 1 10 3 5 12 
29 Zinc 9 2 1 7 2 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 1 1 1 2 1 1 2 2 1 1 2 1 24 124 114 28 100/60 1 2 1 1 1 9 6700 33/59/8/0 195000 2 1 7 0 7 2 2 7 
30 Placebo 12 1 1 5 2 2 2 2 1 2 2 2 1 1 2 1 2 2 2 2 2 2 1 1 2 2 1 2 2 2 1 2 1 28 148 104 24 100/70 1 2 1 1 1 9 6300 71/23/5/1 170000 1 1 7 2 10 3 8 12 
31 Zinc 1 1 1 6 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 8 77 120 28 90/60 2 2 1 2 1 9.5 8800 48/47/5/0 156000 2 1 10 4 7 1 2 13 
32 Placebo 10 2 1 7 2 2 2 1 1 2 1 2 1 2 1 1 2 2 2 2 2 1 1 1 2 2 1 2 2 1 1 2 1 25 123 113 24 110/60 1 2 1 2 1 9.6 5700 36/58/5/1 213000 2 1 10 3 10 3 5 13 
33 Placebo 2 1 1 5 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2 2 1 2 2 10 84 123 32 90/50 2 2 1 1 1 10 5300 38/55/7/0 245000 2 1 8 3 7 2 2 10 
34 Placebo 10 2 2 8 2 2 2 1 1 2 1 2 2 2 1 2 2 2 2 2 2 2 1 1 2 1 1 2 2 1 1 2 1 26 126 119 27 100/60 1 2 1 1 1 9.6 4600 38/58/4/0 265000 1 2 10 2 10 4 6 12 
35 Zinc 11 1 1 6 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 1 1 1 1 2 1 1 2 2 1 1 2 1 27 125 113 26 100/70 1 2 1 1 1 11 4500 40/55/5/0 235000 2 1 9 3 9 3 4 12 
36 Placebo 10 1 1 5 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 2 1 1 1 1 2 1 1 2 2 1 2 2 1 24 124 116 28 100/60 1 2 1 1 1 10 4800 42/56/2/0 172000 2 1 8 3 7 2 2 12 
37 Zinc 11 1 1 7 1 2 2 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 1 21 119 110 24 110/60 1 2 1 1 1 11.4 6600 67/31/2/0 167000 2 1 10 3 9 3 4 11 
38 Placebo 8 2 2 10 1 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 1 1 2 2 2 1 2 2 2 2 2 18 122 116 26 106/60 2 2 2 1 2 12 10800 52/44/4/0 313000 1 2 10 0 6 0 1 6 
39 Placebo 6 1 2 8 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 1 1 2 2 2 1 2 2 1 2 1 18 116 119 26 90/50 2 2 1 1 2 10 3800 60/34/5/1 187000 1 2 8 0 6 0 1 6 
40 Placebo 10 1 1 4 2 2 2 1 1 2 1 2 1 2 1 1 2 2 2 2 1 2 1 1 2 2 1 3 2 1 2 2 2 31 128 112 24 100/60 1 2 1 2 1 11 5000 56/40/2/2 237000 2 1 6 2 9 3 4 11 
41 Placebo 7 2 1 3 2 2 2 1 1 2 2 2 1 2 1 2 2 2 2 2 1 2 1 1 2 2 2 2 2 1 2 2 1 15 108 110 24 100/60 2 2 1 2 1 11 7300 58/38/3/1 242000 2 1 6 3 6 0 1 11 
42 Zinc 12 1 1 3 2 2 2 1 1 2 2 2 1 1 2 1 2 2 2 2 1 2 1 1 2 2 1 2 2 1 2 2 1 24 137 106 23 110/60 2 1 1 1 1 12 4600 56/42/2/0 198000 2 1 5 1 7 1 2 8 
43 Placebo 8 2 1 2 1 2 2 1 1 2 2 2 1 2 1 1 1 2 2 2 2 2 1 1 2 2 2 2 2 1 1 2 2 20 123 118 26 98/62 2 1 1 1 1 11 12000 46/42/7/5 276000 2 1 6 4 6 0 1 11 
44 Placebo 8 2 1 7 1 2 2 1 1 1 2 2 1 2 1 1 1 2 2 2 2 2 1 1 2 2 1 3 2 1 1 2 2 28 122 112 24 94/60 1 1 1 1 1 10.7 11000 45/47/8/0 337000 2 1 11 4 10 3 7 14 
45 Zinc 5 2 1 5 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 1 1 2 2 13 105 110 30 90/60 2 2 1 2 1 11 8700 48/38/9/5 317000 2 1 8 3 8 0 3 11 
46 Zinc 9 1 2 3 1 2 2 1 1 1 1 2 1 1 2 1 1 2 2 2 2 2 1 1 2 2 1 2 1 2 1 2 2 27 130 128 30 100/60 1 2 1 1 1 11 4900 69/19/11/1 185000 1 2 7 4 8 2 3 12 
47 Zinc 10 1 1 5 2 2 2 2 1 2 2 2 1 1 2 2 2 2 2 2 2 2 1 1 2 1 1 2 2 1 1 2 1 25 127 109 25 100/70 1 2 1 1 1 11 8600 38/60/2/0 278000 2 1 8 3 7 2 2 10 
48 Placebo 9 1 1 5 2 2 2 1 1 2 1 2 1 1 2 2 2 2 2 2 2 1 1 1 2 1 1 2 2 1 1 2 1 23 122 110 28 106/72 1 2 1 1 1 11.4 2800 28/62/8/2 195000 2 1 8 3 9 3 4 12 
49 Zinc 5 2 1 10 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2 1 2 2 2 18 113 90 18 110/60 2 2 1 1 2 11 7900 52/40/6/2 205000 2 1 12 2 8 0 3 11 
50 Zinc 5 1 2 9 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 1 15 106 116 24 90/50 2 2 1 1 2 10 7700 51/43/5/1 365000 1 2 9 0 7 2 2 8 
51 Placebo 5 1 2 6 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 1 3 2 1 1 2 2 18 105 118 29 100/50 2 2 1 1 2 10.6 4200 67/30/3/0 102000 1 2 8 2 8 2 3 12 
52 Placebo 8 2 1 3 2 2 2 1 1 2 2 2 1 1 1 1 2 2 2 2 2 2 1 1 2 2 1 2 2 1 1 2 1 20 123 110 24 100/50 2 2 1 1 1 10.2 5600 54/42/4/0 148000 2 1 4 1 8 2 3 9 
53 Placebo 8 2 1 8 2 2 2 1 1 2 2 2 1 1 1 1 1 2 2 2 2 2 1 1 2 2 1 3 2 1 2 2 2 21 127 120 24 100/60 1 1 1 1 1 11.2 3700 80/17/3/0 107000 1 1 10 2 10 2 7 12 
54 Zinc 8 2 2 10 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2 2 1 2 1 17 113 92 18 100/60 2 2 1 1 2 8.9 8000 34/55/10/1 500000 1 2 10 0 6 0 1 6 
55 Placebo 7 1 2 8 2 2 2 2 1 2 2 2 1 2 1 2 2 2 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 18 115 113 27 96/60 2 2 1 2 2 12 5300 44/52/4/0 187000 1 2 9 1 7 2 2 8 
56 Placebo 4 1 1 6 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 2 1 1 2 2 2 1 2 1 14 98 118 32 90/56 2 2 1 2 2 11 3300 40/54/6/0 227000 2 1 8 2 10 3 6 12 
57 Zinc 3 1 1 5 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2 1 1 2 2 13 95 120 30 100/60 1 2 1 1 1 11 6900 32/57/8/3 141000 1 1 9 4 10 4 6 14 
58 Placebo 8 1 1 8 2 2 2 1 1 2 2 2 1 2 1 2 1 2 2 2 2 2 1 1 2 2 1 2 2 1 1 2 1 18 114 116 30 100/70 1 2 1 1 1 9 4600 54/40/4/2 236000 2 1 10 2 7 2 2 9 
 
 
